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S U M M A R Y
6.7 dideoxy-ex-D-gluco-heptose 7-phosphonic acid, the 
isosteric phosphonate analogue of naturally-occurring glucose
6 -phosphate was synthesised via a novel route, involving the use 
of an easily-prepared and stable ethyl ester, followed by a facile 
dealkylation procedure,
6.7 dideoxy a-D-gluco-heptose 7-phosphonic acid was shown 
to behave as a product inhibitor of purified bovine brain 
hexokinase I, being a competitive inhibitor of MgATP^ and a 
noncompetitive inhibitor of glucose.
6.7 dideoxy a-D-gluco-heptonic 7-phosphonic acid, the 
isoteric phosphonate analogue of gluconate 6 -phosphate was 
enzymically synthesised from 6,7 dideoxy a-D-gluco heptose
7-phosphonic acid and was shown to be a poor substrate for 
yeast gluconate 6 -phosphate dehydrogenase at pH 7.5 and 8.0.
6.7 dideoxy «-D-gluco-heptose 7-phosphonic acid had no 
effect on cell proliferation of mouse lymphoma cells (at mM 
concentrations) but was found to be more stable then the natural 
phosphate in their presence.
a-D-glucose fluorophosphate was tes ted , as ;.an activeisitërdireeted 
irreversible inhibitor of yeast glucose 6 -phosphate dehydrogenase with 
a view to eventual use of the corresponding phosphonate analogue 
in similar systems. The fluorophosphate was found to be inactive 
in this respect.
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The isolation and characterisation of fructose 1,6-bis- 
phosphate by Harden & Young in 1905 emphasised the importance of 
phosphorus-containing compounds in living organisms. Organic phos­
phates have since been found to be widely distributed in nature being 
present in all living cells and playing an essential role in metabolic 
processes. Naturally-occurring phosphates are generally of the 
structural type (I) where R or R* or both are organic groupings
0
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(e.g. sugar, lipid or nucleotide) and the compounds can be described 
as mono (R or R* = H) or diesters of phosphoric acid (II). In view 
of the importance of such phosphates in metabolism there has been
0
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considerable interest in the possible use in biological research of 
structural analogues of these compounds. Analogues of naturally- 
occurring metabolites in general have potential as metabolic probes. 
There is always the possibility that an analogue might proceed several 
steps along a metabolic pathway and then not be metabolised further; 
such a situation can lead to the build up of intermediates and so give 
information about the pathway concerned. Possible selective substrate 
and inhibitory activity of this type can lead to chemotherapeutic
-2-
agents capable of blocking pathways in specific pathogenic cells. 
Substrate analogues also have a place in isolated enzyme studies, 
e.g. analogues acting as slow substrates can lead to information 
about enzyme mechanism.
Many kinds of phosphate analogue are possible. The formula 
(I) of naturally-occurring phosphates can be further generalised to 
give the structure (III) in which W, X, Y and Z all represent oxygen
W
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atoms. Analogues in which W, X, Y or Z have been substituted with 
electronegative groups such as -S- or -NH- have been synthesised and 
studied (as indeed have analogues where the phosphorus atom itself 
has been substituted). Replacement of X or Y, not with electro­
negative groups but with substituted carbon atoms leads to phos- , 
phonates (IV) or to phosphinates (V) [derivatives of phosphonic acid 
(VI) or phosphinic acid (VII) respectively].
0 0
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In this thesis we shall be mainly concerned with the occur­
rence, synthesis and biological activity of phosphonates having the 








Over the last twenty years there has been significant 
interest in the preparation and biological investigation of phos­
phonate analogues of naturally-occurring phosphates (Engel 1977).
The minimal structural alteration of substituting one of the ester 
oxygen atoms attached to phosphorus (i.e. X or Y in structure III) 
with a methylene group brings about several physical and chemical 
changes which could have a profound effect on the biological and 
chemical activity of the compound.
The replacement of a phosphate ester C-O-P bond with 
C-C-P in a phosphonate analogue makes such an analogue an unlikely 
substrate for enzymes catalysing phosphate cleavage, although there 
is a good chance that it may act as an inhibitor. This situation 
could lead to a metabolic block and to information about the pathway 
as discussed earlier (page 1-2). The inability of the phosphonate
-4-
grouping to be hydrolysed by phosphatase enzymes is of potential 
advantage in protecting an analogue from unwanted degradation e.g. 
in preserving a metabolic regulator vivo or in stabilising a 
ligand for affinity chromatographic purification of phosphate 
cleaving enzymes (M. Landt e^ £l^., 1978).
A further result of replacement of C-O-P by C-C-P is the 
generally-observed weaker acidity of the phosphonate analogue 
(Freedman & Doak, 1957). This can be seen as resulting from the 
replacement of an electronegative oxygen atom by an electron- 
donating alkyl group. For example glucose 6 -phosphate (IX) with a 
H^O^P 0 CH
secondary pka value of 6.21 will contain approximately 95% of the 
dianionic form at both pH 7.5 and pH 8.0. The isosteric phosphonate 
analogue (X) in contrast has a secondary pka value of 7.46 and will
HgOgP CH^  CH^
X
contain 52% and 78% of the dianionic form at pH 7.5 and pH 8.0 
respectively. This decrease in acidity could have a profound effect 
on the activity of phosphonates as substrates of enzymes where the 
dianionic form of the substrate is necessary for reaction. Such a
-5-
situation could be exploited to investigate preferred binding modes 
in enzyme-substrate interactions. Phosphonates of the type (III) 
where W  = X  = Z = 0 and Y = -C- can of course, only ever exist in the 
mono anionic form and could be used in similar studies.
Phosphonate analogues can also differ from the natural 
phosphates in their physical size and shape. Although the phosphon­
ate analogue in which C-O-P of a natural substrate is replaced by 
C-CH^-P is designed to mimic the naturally-occurring phosphate in 
bond lengths and angles, differences can occur. Such differences 
in ’isosteric' analogues of the type so far discussed, while possibly 
biochemically significant are usually physically small. However 
methylene diphosphonic acid (XI) the isosteric phosphonate analogue 
of pyrophosphoric acid (XII) has differences in the P-X-P bond angles 
of greater than 10° (Larson et al., 1969). Discrepances of this kind 
can lead to large differences in binding properties for the analogues
HgO^P CH PO 3 H H^O^P 0 PO 3 H 2
XI XII
of nucleotide di- and triphosphates where a pyrophosphate linkage has 
been replaced by a methylene diphosphonate finkage. Many analogues in 
which the C-O-P of a natural phosphate is replaced simply by C-P have 
also been studied and in such "non-isosteric" analogues there is an 
obvious decrease in the overall size. Furthermore the distance
—6-
between the phosphoryl oxygens and other possible binding sites or sites 
of interaction are significantly changed unless strained or unlikely 
conformations occur. This could result in far greater variation of 
biochemical activity than that brought about by simple substitution 
of a methylene group for an oxygen atom. For this reason "isosteric" 
phosphonate analogues might in principle be considered to be better 
analogues.
A  final difference between phosphonate analogues and the 
natural phosphates is the loss of a possible binding function of the 
esterified phosphate oxygen which is absent in the analogue.
The isolation of naturally-occurring phosphonates 
(Horiguchi & Kandatsu, 1959) from living organisms has stimulated many 
biochemical investigations. Mutant strains of bacteria have been 
shown to be capable of using phosphonates as a source of phosphorus, 
(Zeleznick e^ aJ., 1963) and a naturally-occurring phosphonate, 
phosphonomycin (XIII) isolated from Streptomyces radiae 
(Hendlin et al., 1969) has been found to have a broad spectrum of
H 0
PO 3 H 2
XIII
antibiotic activity caused by its inhibition of bacterial cell wall 
biosynthesis.
Phosphonates have been shown to occur commonly among lower 
animals (Kitteridge & Roberts, 1969) chiefly in the form of a-amino
-7-
ethyl phosphonate (XIV) and its derivatives and La Nauze et al. (1970) have
H 2 O 3 PCH 2 CH 2 NH 2  H 2 O 3 P CH^CHO
XIV XV
purified (from a strain of Bacillus cereus) an enzyme able to cleave 
the C-P bond of 2 phosphono acetaldehyde (XV) itself a product of 
2 amino-ethyl phosphonate.
Thus phosphonates as analogues of naturally-occurring phos­
phates are of interest and of possible potential use in biochemical 
investigations as probes of metabolic pathways and of enzyme 
mechanisms,^s chemotherapeutic agents and as stable ligands in 
affinity chromatographic purification of phosphate-cleaving enzymes. 
The following introduction will point out the various kinds of phos­




1. Analogues of ATP
The central role that ATP plays in many biochemical processes 
has led to an extensive study of the phosphonate analogues XVI and XVII in 











(i) Systems in which phosphonate analogues have been found to be 
capable of replacing ATP
Analogue XVI was found to be a substrate for RNA polymerase 
(Azotobacter vinelandii) allowing incorporation of labelled UMP into 
Poly Au 30% to 60% as effectively as when ATP was used (Simon et al., 
1965) . Wong & Murray (1969) showed that analogue XVI is also a good 
substrate for phosphoribosyl pyrophosphate synthetase from Ehrlich 








the cleavage of the a3 phosphodiester bond of ATP (unchanged in 
analogue XVI) and the substrate activity of XVI is perhaps not
-9-
surprising.
Analogue XVI, like ATP, was found to regulate the activity 
of adenylate deaminase in crude extracts of ascites-tumour cells 
(Atkinson & Murray, 1967). It should be noted that the similar 
activities of compound XVI and ATP in this crude extract could result 
from competing factors. Thus analogue XVI is unlikely to be removed 
in kinase-catalysed reactions and so any diminished regulatory 
activity compared to that of ATP could be compensated by its longer 
lifetime in the system.
Phosphonate analogues XVI, XVII and XVIII were all found 
to be good inhibitors of rabbit liver fructose 1 , 6 bisphosphatase, 
but the deoxy analogue XIX had no inhibitory action (Table 2). The
Table 2
addition [concnQ relative activity
none 1 0 0 %
XVI 0.005mM 49%
XVII 0.1 mM 35%
XVIII 0.1 mM 6 6 %
XIX 0.1 mM 107%
XXII 0.1 -> 0.9mM 104 -> 90%
0 0 0
I II I
H 0 P-CH -P-O-P-O-P-O-CH





2 3 2 I I 1 ^ 0 ^  A
OH OH f V ,
OH
XVIII XIX
action of analogue XIX is in contrast to that of the natural 2 deoxy-
OH OH
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ATP which is a more effective inactivator than ATP. These results 
are difficult to interpret and the authors suggested that they were 
an exaggeration of the random specificity exhibited by the natural 
nucleotide di and tri phosphates (Taketa ^  £ l , , 1971).
Analogue XVI was found to be a better inhibitor of bacterial 
polynucleotide phosphorylase than was ATP (Simon & Myers, 1961).
Flesher e_t a l . (1960) found that analogue XVI was over 
twenty times more potent than ATP in increasing the vasodepressor 
activity of 'nembutal* - anaethetized cats. This indicates that the 
mechanism of action of ATP is the result of binding to a receptor site 
without cleavage of the phosphate chain. The increase in activity of 
analogue XVI compared to that of ATP was rationalised as resulting 
from small deviations in bond angle and lengths around the substituted 
methylene group which might afford greater affinity for the receptor 
site.
Issaly ^  a T . (1973) demonstrated that the phosphonate XVI 
could replace ATP in promoting the release of aspartate transcarba- 
mylase from ribosomes of a mutant strain of Neurosporo crassa in vitro 
after complementation (Table 3). However analogue XVII did not 
replace ATP in this system and it was concluded that the major
Table 3. Release of aspartate transcarbamylase by nucleotides







mechanism of ATP involved either transfer or liberation of a pyro­
phosphate group.
Yount et^  al. (1971b) showed that analogue XVI forms one to
2+ 2+ 2+ . 
one complexes with Ca , Mg and Mn cations with affinities equal
to, or greater than, those of ATP. This was found to be true at 
pH 7.4 where protons might be expected to compete effectively with 
divalent metal ions for the weaker acid group of the phosphonate 
analogue. This suggests that any failure of XVI in enzymic inter­
actions cannot be attributed to inability to bind divalent metal ions
The above activities of analogues XVI and XVII as ATP 
analogues are listed in Table 4 together with some further reported 
instances.
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Table 4. Systems where analogues of ATP are capable of replacing ATP
Analogue System Effect Reference
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XVI adenylate
deaminase
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XVI release of 
ATCase from 
ribosomes of a 









Analogue System Effect Reference














Duree et a l . 
(1968)
XVI production of 
relaxed state in 
insect flight 
muscle
same as ATP Goody et al. 
(1975)
XVII early burst hydrolysis 
of ATP by Myosin
same as ATP Koretz & 
Taylor (1975)
-14“
(ii) Systems in which Phosphonate analogues have been found not to 
be capable of replacing ATP
Phosphoenolpyruvate synthetase from E. coli catalyses the 
overall reaction
ATP + pyruvate phosphoenol pyruvate + AMP + P^.
Analogue XVI was not a substrate for this enzyme but found to be a 
competitive inhibitor with respect to ATP (K^ = 2.lyM)(Berman & Cohn, 
1970). Preliminary incubation of the synthetase with XVI (in contrast 
to ATP, Table 5) did not block subsequent phosphorylation of the 
enzyme with phosphoenolpyruvate nor did it block the pyruvate -
Table 5
preincubation compound moles P^/mole enzyme
none 1.3
ATP 0 . 0
XVI 1 . 1
phosphoenolpyruvate exchange reaction. This was interpreted to show 
that a pyrophosphotyl enzyme intermediate (E-PP) is not formed (for 
in such a case analogue XVI might be expected to form an inactive 
E-PCH^P intermediate which would block both phosphorylation of the 
enzyme with phosphoenolpyruvate and the exchange reaction of C_| 
pyruvate and phosphoenolpyruvate.
Lin ^  al. (1975) found analogues XVII and XVIII to be 
competitive inhibitors of hepatic adenylate cyclase with respect to 
ATP (Table 6 ).
-15-
Table 6
Compound K (uM) 
m




XXIV ' - 2 0 0
The ionic form of the analogues is not likely to be a major factor in
these inhibitions as the K. values obtained were identical at pH 7.5
1
and 8.0. These results also indicate that the active site of hepatic 
adenyl cyclase can accommodate an extra phosphate group on the 
nucleotide (e.g. XVIII) without a reduction in affinity compared to 
ATP.
Both analogues XVI and XVII were found to behave as com­
petitive inhibitors of ATP with formyl tetrahydrofolate synthetase 
from Clostridium cylindrosporum (K^ values 10 and 28yM respectively 
compared to a value for ATP of 200yM)(Curthoys & Rabinowitz, 1971), 
The authors pointed out that the high affinity of the analogues for 
the enzyme might be explained in terms of their superior ability to 
achieve a trigonal-bipy-ramidal intermediate because of small deviat­
ions in bond angles and lengths around the substituted -CHg- group.
Further studies by Buttlaire & Reed (1975) found that, in contrast to
2+
the EPR spectra of the ATP-Mn - formyltetrahydrofolate synthetase
complex, that of the corresponding analogue XVI complex showed con-
2+
siderable broadening of the spectrum of Mn . Other differences from 
the ATP-containing complex were also noted and were attributed to the 
presence in the analogue of the P-C-P linkage which could affect the
— 16-
capacity of the synthetase to undergo certain conformational changes
Microsomal preparations of Na*, K^-dependent ATPase from 
porcine kidney outer medulla and from Electrophorus electroplax 
catalysed a rapid Mg^* and dependent exchange of water oxygens 
( ^ 2  ^ with inorganic phosphate (Dahms & Boyer, 1973) in the 
presence of ATP. Analogue XVI was unable to replace ATP in acti­
vating exchange of water oxygens from the medium to inorganic phos­
phate, indicating that the exchange arises by dynamic reversal of a 
late step in ATP hydrolysis by the Na*, K^-dependent ATPase.
In similar studies Holland & Labelle (1974) investigated 
the effect of replacing ATP by analogue XVI in oxygen-exchange 
reactions catalysed by rat liver mitochondria. Under conditions 
where rapid exchange of H ^ [^^0 ] with the terminal phosphate oxygens 
of ATP occurred (unique to oxidative phosphorylation) analogue XVI 
displayed no incorporation of labelled oxygen from This
suggests that ATP-water exchange can only occur when the terminal 
phosphate can be cleaved. Alternatively the analogue may not bind 
at the site where exchange takes place, or the analogue may bind at 
this site but not form the penta-covalent intermediate. Analogue XVI 
was found not to inhibit the above exchange between ATP and labelled 
water (H^ ) » but did on the other hand inhibit the exchange
between inorganic phosphate and H^ [^^0 _| and the exchange between 
phosphate and ATP. These results suggest the presence of separate 
sites for ATP in these exchange reactions (Holland & Labelle, 1974).
Moos at al^ . (1960) first reported investigations on the 
effects of substituting analogue XVI for ATP in muscle contraction.
-17-
Analogue XVI was found not to be able to replace ATP in causing muscle
contraction or in lowering the viscosity of actomyosin and was not
hydrolysed by a homogenate of glycerinated muscle. It was shown to
2+
partially inhibit myofibrillar ATPase but the presence of Mg 
abolished the inhibition. Analogue XX was also shown not to induce 
contraction of myofibrils nor to be hydrolysed by myosin b 
(Tonomura ^  , 1967) suggesting that ATP must be in the dianionic
form for the hydrolysis to occur.
0 0 0
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Inhibition of heavy meromyosin ATPase by analogue XVI was 
found (Yount e_t a l ., 1971a) to be mixed in the presence of Mn^^ or Mg^* 
(K^ values 44 and 200yM respectively). This inhibition levelled off 
at higher concentrations of analogue XVI which may represent inter­
action of the analogue with a second modifier site.
Werber al. (1972) found that ATP, but not analogue XVI, 
induced fluorescence changes in heavy meromyosin, suggesting that the 
observed changes resulted from local conformational changes of heavy 
meromyosin induced by cleavage of the terminal phosphate group of ATP. 
Further studies by Seidal (1975) showed that ATP-induced enhancement 
of fluorescence and changes in the EPR spectra of myosin and heavy 
meromyosin, represented firstly, the binding and secondly, the 
hydrolysis of ATP. Analogue XVII was shown to be capable of binding 
to myosin but was not subsequently hydrolysed. Koretz & Taylor (1975) 
demonstrated that myosin gave an ’early burst' of 0.25 ■> 0.3 protons/
-18-
active site with both ATP and analogue XVII. The proton liberation 
was assumed to be derived from a change in conformation of the enzyme- 
substrate complex.
The actin monomer of G-actin, binds one molecule of ADP or 
ATP which is rapidly exchanged with unbound nucleotides and was found 
to bind analogues XVI and XVII only with an affinity 100 to 200 fold 
less than ATP, indicating the very specific nature of this binding 
site ( Cook & Murdoch, 1973).
These and similar activities of the phosphonate analogues 
of ATP are listed in Table 7.
“19”
Table 7 . Systems where analogues of ATP have been found not to be 
capable of replacing ATP
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binding
Tobin et al, 
(1973)
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ATPase (Na* K* 
dependent, 
porcine kidney) 
ATPase (Na* K* 
dependent, Electro- 
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Analogue System Effect Reference






XVI yeast hexokinase (activates
pH 6 .6 ) (inhibits
pH 8.0)
Kosow & Rose 
(1971)
XVI actomyosin inhibits Moos £t al^., 
(1960)
XX myosin b no action Tonomura et al. 
(1967)




presence of Mg^ 
2 +
or Mn
Yount et a l . 
(1971a)
XVI A T P , heavy mero­
myosin interaction
did not replace 
ATP




bound but not 
hydrolysed Santi (1975)
XVI myosin early burst of 
protons but not 
hydrolysed




G-actin bound > xlOO 
more weakly
Cook & Murdoch 
(1973)
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(iii) Interaction of amino acyl- tRNA synthetases with analogues of ATP
Papas & Case (1970) observed a broad range of responses of
various amino acyl-'tRNA synthetases from E. Coli to analogue XVI.
The analogue showed substrate activity with some synthetases having
K values similar to or slightly lower than those of ATP, but Vm  o  j max
values were all lower than those of the natural substrate (e.g. 50%
for lysyl-t RNA^< 1% for glycyl- t R N A ) . In the case of synthetases where
the analogue was not a substrate but did competitively inhibit ATP,
K. values ranged from 0.02 to 10 times the K value of ATP.
1 m
Analogue XVII was found (Santi et al., 1971) to be a non­
competitive inhibitor of phenyl alanyl-tRNA synthetase from E. ç oil 
(indicating the presence of an alternative binding site for adenine 
nucleotide phosphates in this enzyme) and was a strong competitve 
inhibitor (K^ = 12yM compared to ATP = 0.5mM) of tyrosyl- tRNA 
synthetase from E. eoli (Santi & Pena, 1973).
Marutzky £ £  a i • (1976) found both analogues XVI and XVII to
be competitive inhibitors of leucyl- tRNA synthetase from E. eoli
(K^ values 0.34 and 0.2mM respectively; for ATP 0.3mM). However
the equivalent imido analogue XXI was able to replace ATP as a sub-
0 0 0
II II II




strate for this reaction (K value = 0.05mM,V 74% of that of ATP).
m  max
The deviations in bond angle and lengths around the methylene sub-
-23-
stituted group in analogue XVI are larger than can be tolerated by 
the triphosphate binding site of this enzyme.
Southgate & Dixon (1978) found that the isosteric phosphonate 
analogue (XXII) of valylyl adenylate (XXIII) bound to valyl- tRNA 
NH_0 0 NH_0 0
CH 3 I 1^1 II CH I 2 || II
^ C H - C H - C - C H - P - O - A  J>>CH-CH-C-0-P-0-A
C H . ^  2  I I
OH OH
XXII XXIII (A = Adenosine)
synthetase (from E. coli) much less tightly than did the natural com-
- 7  - 1 1  - 9
pound (dissociation constants, 5 x 10 M  and 10 to 10 
respectively). However analogue XXII inhibited both ATP-inorganic 
pyrophosphate exchange and valylation of tRNA by valyl- tRNA syn­
thetase (K^, 3yM). The authors suggested that reduced binding of 
analogue XXII to the synthetase might result because interaction of 
the enzyme with valylyl adenylate depends upon the anhydride oxygen, 
missing in the analogue.
—24“
2. Analogues of A D P .
(i) Systems in which phosphonate analogues have been found
to be capable of replacing ADP







replace ADP in inducing human platelet aggregation and could inhibit 
ADP induced aggregation. Furthermore the rate of analogue XXIV - 
induced aggregation was found to increase on raising the pH of the 
platelet-rich plasma above the pKa of the secondary phosphoryl 
dissociation of the analogue. These results suggest that analogue 
XXIV acts at the same site as ADP on platelet membrane and that 
hydrolysis of ADP is not a prerequisite for the process of aggregation, 
The observed effect of pH on the rate of analogue XXIV - induced 
aggregation indicates the importance of the ionization state of the 
terminal acid group of the nucleotide. Even when fully ionised, 
however, analogue XXIV is a much less potent aggregating agent 
than ADP, probably because of conformational differences between the 
two compounds [Gough e_t al. (1972) working with sheep platelets 
obtained somewhat different results from the above"] . These and some 
further activities of analogue XXIV are listed in Table 8 .
-25-
Table 8 . Systems where analogues of ADP are capable of replacing ADP
Analogue System effect Reference
XXIV blood platelet 
aggregation
induce aggregation Horak & Barton 
(1974)
XXIV exchange of nucleotides 
from mitochondria
as ADP but slower Duree et al. 
(1968)
XXIV exchange of nucleotides 
from (yeast) 
mitochondria
as ADP but slower Lauquin & 
Vignais (1973)
XXIV exchange of nucleotides 
from (rat and mouse 
liver) mitochondria
as ADP but slower Jebeleann
(1974)



















Evans & Gurd 
(1973)
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(ii) Systems in which phosphonate analogues have been found not 
to be capable of replacing ADP
Le Blanc & Clauser (1974) showed that respiration-dependent
2+
Ca accumulation in hog heart mitochondria has a specific requirement
for ADP. Analogue XXIV was found to be unable to substitute for ADP
2+




Ca uptake (yatoms/mg protein/10 mins)
none 0.65
ADP 2.4mM 1 . 2
XXIV 2.4mM 0.16
Binnet & Volfin (1974) demonstrated that internal ADP in
rat liver mitochondria is necessary in order that a cytosolic metabolic
2+ 24-
factor (cmf) can exert its protective effect against Mg and Ca 
release from the mitochondria. Analogue XXIV was shown significantly 
to decrease the effect of cmf and this effect of XXIV was negated by 
the presence of atractylate. Analogue XXIV probably acts by depleting 
the endogenous ADP from the mitochondria.
Analogue XXIV inhibited the phosphorolysis of oligo- and 
polynucleotides (to yield ADP) by polynucleotide phosphorylase from 
Micrococcus luteus (Chou & Singer, 1970). At concentrations up to 
ten times those at which deoxy ADP afforded 50% inhibition analogue XXIV 
was neither a substrate nor an inhibitor of de novo ADP polymer is ation 
catalysed by this enzyme (Chou & Singer, 19 71). When the analogue 
(XXIV) concentration was raised to levels equivalent to that of the
-27-
ADP substrate (20mM) significant inhibition of polymerisation did, 
however, occur. Letendre & Singer (1974) tested the effects of ADP 
and analogue XXIV on the interaction of N-ethylmaleimide and poly­
nucleotide phosphorylase from Micrococcus luteus (Table 10). In
Table 10
addition
effect of reaction with N-ethylmaleimide 
mole / mole enzyme
without dithiothreitol with dithiothreitol
none 0.7 2.5
ADP 0 . 2 1.7
none 0.3 2.3
XXIV 0.3 1 . 6
contrast to ADP, analogue XXIV did not effect the reaction of the 
immediately-available sulphydryl groups with N-ethyl maleimide.
Raue & Cashel (1974) demonstrated that E. coli subjected to simultaneous 
temperature and osmotic shock are capable of carrying out exchange 
between inorganic phosphate and ribonucleotide 5 ’polyphosphate.
The fact that analogue XXIV inhibited this reaction was interpreted, 
together with other evidence,as indicating that this reaction is 
catalysed by polynucleotide phosphorylase.
Interestingly, analogue XXIV did not cause any decrease in 
rabbit muscle fructose 1,6 bisphosphatase activity, although ADP was 
found to be the most effective natural nucleotide phosphate inhibitor 
tested (Table 2) but at high concentrations analogue XXIV did give 
some protection against ATP inactivation (Taketa e£ a^., 1971).
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Analogue XXIV did not inhibit ATP binding to formyl tetra- 
hydrofolate synthetase from Clostridium cylindrosporum (Curthoys & 
Rabinowitz, 1971) nor did it change the EPR spectrum of myosin 
(during steady state hydrolysis) indicating either that it does not 
bind or that binding produces no spectral changes (Seidal, 1975).
Although proton relaxation rate measurements showed that
2+
analogue XXIV forms a ternary complex with Mn and creatine kinase 
from rabbit muscle it was found to be neither a substrate nor an 
inhibitor of the reaction catalysed by this enzyme (O’Sullivan et al., 
1972).
Gough e_t £l. (1972) reported that analogue XXIV does not 
initiate aggregation of sheep platelets (or inhibit ADP initiation) 
which was taken to indicate that hydrolyses of ADP is a necessary, 
key energy-providing reaction in platelet aggregation (c.f. Horak & 
Barton, 1974, page 24).
In mitochondrial and chloroplast ATP formation, inorganic 
phosphate loses an oxygen to water. ADP is the first detected 
acceptor of the phosphoryl group. Analogue XXIV was found (Jones & 
Boyer, 1969) not to be detectably phosphorylated; not to stimulate 
the exchange of oxygen from inorganic phosphate to water in the 
absence of ADP and not to inhibit this exchange in the presence of 
ADP. These results are consistent with the theory that exchange of 
inorganic phosphate oxygen with water results from the dynamic 
reversal of ATP formation at the catalytic site and that in the 
phosphorylation reaction the first covalent compound formed is that 
between inorganic phosphate and ADP.
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These and some other activities of the phosphonate analogues 







Table 11. Systems where ADP analogues have been found not to be capable 
of replacing ADP
Analogue System Effect Ref.
XXIV Ca^* accumulation in 
mitochondria (hog heart)
inhibits ADP depend- 
2 +
ent Ca accumulatioi
Le Blanc & 
1 Clauser 
(1974)
XXIV mitochondria (rat 
liver) cytosolic meta­
bolic factor
inhibited A D P ’s 
action on cmf
2 +




XXV phenylalanyl tRNA 
synthetase (E.coli) non comp, 
inhibitor








not a substrate 






no effect on 






inhibitor Raue & Cashel 
(1974)
XXIV fructose 1 , 6  bisphos­
phatase (rabbit muscle)
not an inhibitor Taketa et al. 
(1971)
XXIV formyl tetrahydro- 
folate synthetase 
(C. cylindrosporum)
not an inhibitor Curthoys & 
Rabinowitz 
(1971)





Analogue System Effect Ref.
XXIV creatine kinase 
(rabbit muscle)
not a substrate or 
inhibitor
O ’Sullivan et al. 
(1972)
XXIV aggregation of 
sheep platelets
does not initiate 
(or inhibit ADP)
Gough et al. 
(1972)
XXIV adenylate kinase, \ 
pyruvate kinase , / 
Hexokinase, ] 
phosphorylation \ 




poor P^ acceptor 
did not inhibit ADP 
-> ATP
Duree et al. 
(1968)
XXIV chloroplasts and 
mitochondria
« 2 ° -  
ADP + H^O+P.:^^ ATP
not phosphorylated 
did not stimulate 
H^O ^  P^ exchange
Jones & Boyer 
(1969)
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3. Analogues of AMP
AMP and its isosteric analogue (XXVI) were both found to be 
competitive inhibitors of adenyl-O-succinate synthetase from E. coli 
(K^ values 32 and 280yM respectively). The decrease in acidity of the
NH
H2O3P-CH-CH H2O3-P-C-CH2
OH OH OH OH
XXVI XXVII
analogue was thought to be the reason for its higher value 
(Hampton & Chu, 1970).
Analogues XXVI and XXVII were found to be substrates or 
competitive inhibitors (or both) for several enzymes (Table 12) 
(Hampton et a l ., 1973a). Action of adenylate kinase on compound XXVI 
led to analogue XXVIII which was shown to be a substrate for pyruvate 
kinase.
Hampton ^  al. (1973b) also investigated the properties of 













rate curve in the presence of AMP amino hydrolase. This resulted from 
different reactivities of the two epimers of analogue XXIX. The V
max
value for the more active epimer was essentially the same as that for 
AMP which was in turn five times greater than that for analogue XXVI. 
The authors suggested that the enhanced substrate activity of the 
active epimer of analogue XXIX might result from an ability of its 
C- 6 ' oxygen atom to mimic the oxygen at C-5’ of the natural phosphate. 
Steric hindrance was put forward as a possible reason for the low 
^max obtained for the less active epimer of analogue XXIX
(eight times lower than that of analogue XXVI). Inhibition of 5 ’ 
nucleotidase by analogue XXIX but not by analogue XXVII can also be 
interpreted in terms of the potential ability of the C- 6 ’ oxygen 
atom of analogue XXIX to mimic some function of the C-5' oxygen 
atom of AMP in the enzyme-AMP interaction. Analogue XXIX was found 
to be a poor substrate for pig and rabbit adenylate kinases and it 
was suggested that the hydroxyl group on C- 6 ’ will be, in this mixture, 
close to the site of the catalysed reaction; steric and electronic 
requirements for substrate activity are likely to be more exacting in 
this area of the enzyme substrate complex (Hampton et al., 1973b).
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Table 12. Effect of AMP analogues with various enzymes
Analogue System Effect Reference





llOyM, (AMP K = 
m
27yM).
Hampton et al. 
(1973a)
XXVI AMP aminohydrolase 
(rabbit muscle)
substrate K = 
m
1.7mM (AMP K = 
m
l.OmM)
Hampton et a l . 
(1973%)
XXVII AMP aminohydrolase 
(rabbit muscle)




inhibitor K. = 
1
19yM
Hampton et al. 
(1973a)
XXIX AMP aminohydrolase 
(rabbit muscle)
epimer I, substrate
K = 4.0mM (V 
m  max






Hampton et al. 
(1973b)
• XXIX AMP aminohydrolase 
(rabbit muscle)
epimer II substrate
K = 0.025mM V
m  max
3% of V value foi 
max
AMP)










substrate K = 
m
0.17mM (AMP K = 
m
0.5mM) V = 2 . 3 %  
max
of V for AMP, 
max
competitive




Hampton eC a l . 
(1973a)
XXVII Adenylate Kinase 
(rabbit muscle)
substrate K = 
m
0.027mM (V 0.4% 
max
of V for AMP), 
max
competitive
inhibitor, K^ = 
0.32mM
Hampton ejt al 
(1973a)
XXIX Adenylate Kinase 
(rabbit muscle)
substrate K = 
m
0.71mM (V = 0.2%
max





4. Analogues of cyclic nucleotides
In a patent, Jones & Moffatt (1969) reported the synthesis of 
the isosteric analogue XXX of 3'5’ cAMP, with equivalent pharmacological 
action to that of the natural compound (XXXI) but with a longer half- 






derivative (XXXII) to have 54% of the activity of cAMP in stimulating
calf brain protein kinase. The isosteric phosphonate ethano derivative
(XXXIII), on the other hand had only 0.46% of the activity of cAMP in










HO = P  — 0
OH
XXXII XXXIII
lene substitution in the 3 ’ (analogue (XXIV) and 5' (analogue XXX)
oxygen position of cAMP on activation of cAMP-dependent and cGMP-dependent
protein kinases from various sources. Analogue XXX was found to
activate cAMP-dependent protein kinases from bovine brain, bovine heart,
rat adipose cells and lobster muscle to the same maximal levels as did
cAMP but at concentrations 25 to 500 fold greater than those of cAMP,
but was inactive with cGMP-dependent protein kinase from lobster muscle.
Analogue XXXIV was found to have no activating effect on either cAMP-
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CH
0 2 P  _ C H  . OH
OH
XXXIV
dependent or cGMP-dependent protein kinases. Similar results were 
obtained for rabbit muscle and bovine brain protein kinase, analogue 
XXXIV showing no binding affinity (Panitz eJt al^., 1975) .
The importance of the position of modification of the methylene 
analogues is also apparent in the cAMP activity of slime mold chemo- 
tactic activity (Malchow e^ a^., 1973). Analogue XXX was found to be as 
active as cAMP in stimulating chemotaxis in Dictyostelium discordeum, 
whereas analogue XXXIV had a 10^ fold-reduced effect. Furthermore the 
hydrolysis of cAMP by particle bound phosphodiesterase of D. discordeum 
was inhibited by analogue XXX 100-fold more effectively than by analogue 
XXXIV. The 3 ’ oxygen of cAMP is obviously more important that the 5' 
oxygen in interaction with protein kinases, phosphodiesterase and proteins 
involved in chemotaxis. As well as studying methylene substitution of 
3' and 5 ’ oxygen atoms of cAMP, Mato & Konijn (1977) have carried out 
studies with imido analogues of cAMP. The cAMP chemoreceptor in
D. discordeum was shown not to differentiate between, -0-. -CH^- or 
-NH- at the 5 ’ position of the phosphate ring. On the other hand the 
3' position of the phosphate showed a much higher degree of specificity 
(-0- > -NH- >> -CH^” ) underlining the importance of the lone electron 
pairs of the C-3' oxygen in interactions of cAMP with proteins.
-38-
In another patent Jones & Moffat (1971) reported the syn­
thesis of the isosteric analogue XXXV of 2*3' cyclic AMP which was 
claimed to be useful for controlling metabolism and producing meta­




XXXV, X = Adenine 
/
HO 0 XXVVI, X = Uridine
found to bind somewhat more strongly to bovine pancreatic ribonuclease
than did the natural substrate 2'3 cUMP (K values 0.13 and 2.2mM
m
respectively), however analogue XXXVI was significantly less susceptible 
to hydrolysis by this enzyme.
Extensive biochemical investigations have been carried out 
on many phosphonate analogues apart from those based on adenine 
nucleotides. The bulk of the literature published in this area has 
tended to emphasise mechanistic aspects, in attempts to clarify the 
biochemical role of the natural nucleotide.
5. Analogues of GTP
(i) Studies on protein synthesis
The isosteric analogue XXXVII of GTP (XXXVI) in which the 
3 y pyrophosphate oxygen is replaced by a methylene group has been 
thoroughly studied in elucidating the role played by GTP in protein 
synthesis. Initial investigations showed analogue XXXVII to be an 
overall inhibitor of peptide synthesis in several systems (Table 13),
A full discussion of this area of work is beyond the scope of the 
present thesis. There have been several reviews on protein synthesis
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(Lippmann, 1969, Lucas-Lenaro & Lippmann, 1971, Haselkorn & 
Rothman-Denes, 1973) covering the use of analogue XXXVII in 
elucidating the role of GTP in protein synthesis. It has been 
demonstrated that GTP participates in initial binding of an amino 
acyl tRNA to the ribosomal complex without pyrophosphate cleavage, 
but that such cleavage does occur during translocation.
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Table 13. Analogues used in investigations to determine role of GTP 
in protein synthesis
Analogue Effect of analogue Reference
XXXVII competitive inhibition of homo- 
polynucleotide synthesis in vitro, 
(E. coli) with respect to GTP
Hershey & Monro 
(1966)
XXXVII inhibition of formyl methionyl- 
puromycin in vitro (E. coli)
Hershey & Tach 
(1967)
XXXVII inhibition of valine incorporation 
into di and oligonucleotides
Tach et a l . (1967)
XXXVII stimulated binding of formyl- 
methionyl-tRNA to E. coli ribo­
somes, but did not replace GTP 
in reaction of formyl-tRNA- 
ribosomes with puromycin
Ohta et al. (1967)
XXXVII . did not inhibit binding of GTP to 
form a guanyl nucleotide-phenyl- 
alanine RNA complex, an inter­
mediate product in enzyme 
transfer of phenylalanyl tRNA 
to ribosomes, but did 
inhibit formation of a 
dipeptide.
Ravel et al. 
(1968)
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(ii) Other studies of phosphonate analogues of GTP
At very low concentrations (O.GSyM) GTP stimulates the rate 
and degree of dissociation of bound, labelled glucagon in plasma 
membranes of rat liver. Analogue XXXVII shows a similar stimulation 
but at 100 times higher concentration than that of GTP (Rodbell e^ a^., 
1971a). The authors suggested two possible explanations for these 
results. Either the analogue might exert its effect on glucagon 
binding by itself binding in a GTP-like manner to the membrane in a 
process not requiring phosphorylation or the analogue may exert its 
action by inhibiting the breakdown of endogenous membrane bound GTP.
Further studies by Rodbell e^ (1971b) showed that GTP 
plays an obligatory role in glucagen-induced activation of adenylate 
cyclase being active at somewhat lower concentrations than those which 
affect glucagon binding (lOnM). In this system analogue XXXVII 
substituted for GTP with similar effectiveness at only five times the 
concentration of GTP (i.e. 50nM). The similar activities of analogue 
XXXVII and GTP indicate that GTP regulates this process through 
binding and not through phosphorylation.^ Salomon^ et al. (1975) also 
showed analogue XXXVII to be capable of substituting for GTP in the 
activation of the hepatic adenylate cyclase system (again less 
effectively than GTP).
In contrast to the above two reports, Cuatrecasas et a l . 
(1975) found that analogue XXXVII stimulated adenylate cyclase in rat 
fat pad membranes (in the presence or absence of hormones) unlike GTP, 
which was found to have no effect. The rate of activation was 
relatively slow and the authors postulated that after forming 
reversible Michaelis complexes of relatively low affinity, analogue
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XXXVII might react irreversibly with the GTP regulatory site of the 
enzyme, perhaps forming analogue-enzyme covalent intermediates which 
maintain the activated state of the enzyme.
The most striking activation of adenylate cyclase by 
analogue XXXVII was reported by Pfeuffer & Helmreich (1975) who 
showed the phosphonate to be ten times more potent than GTP in 
activating pigeon erythrocyte membrane adenylate cyclase. The authors 
concluded that analogue XXXVII binds non-covalently to the GTP site 
on the membrane causing an unphysiological, irreversible activation of 
membrane-bound adenylate cyclase.
Kuwano ^  al. (1969) isolated a ribonuclease (Ribonuclease V) 
from cell-free extracts of E. coli and described some of its properties 
which suggest that ribonuclease V acts as a mRNase in the cell.
Analogue XXXVII was not a substrate for but competitively inhibited 
ribonuclease V activity indicating that hydrolysis of GTP is necessary 
for RNase V function.
Purified tubulin from bovine brain is made up of a dimer 
which contains two binding sites for guanyl nucleotides. One contains 
a tightly-bound GDP molecule which is phosphorylated by GTP bound at 
an exchangeable site. Analogue XXXVII was not effective in displacing 
labelled GTP from the exchangeable binding site on tubulin, whereas 
the imido analogue could do this (Arai e_t al^ ., 1975) . Similar results 
were obtained for the assembly of bovine neurotubules (Sutherland,
1976). This provides further evidence that mild deviations in bond 
angles and lengths resulting from the substitution of a methylene 
group for an oxygen can result in changes in biochemical activity. 
Macconi & Seeds (1977) found that neither analogues XXXVII nor XXXIX 









Analogue XXXVII was found to be a competitive inhibitor of 
GTP with respect to the action of adenylosuccinate synthetase from
E. coli (K^ = 80yM) showing no substrate activity (Rudolph & Fromm, 
1969).
Raue & Cashel (1974) found that analogue XXXVII could not 
replace GTP in stimulating polynucleotide phosphorylase from E. coli, 
indicating that hydrolysis of the 3 y phospho diester bond is required 
for GTP to be active in the exchange between inorganic phosphate and 
ribonucleoside 5 ’ polyphosphate.
These effects of the phosphonate analogues of GTP are listed 
in Table 14.
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Table 14. Studies on analogues of GTP
Analogue System Effect Reference
XXXVII plasma membrane of rat 
liver '
release of glucagon 
bound to membrane 
xlOO [ ] o f  XXXVII 
needed for same, 
effect as GTP
Rodbell et al. 
(1971a)
XXXVII activation of adenyl 
cyclase
x 5 [ ”|of XXXVII 
needed for same 
effect as GTP
Rodbell et al. 
(1971b)
XXXVII activation of adenyl 
cyclase (hepatic)
x5 [ ]  of XXXVII 
needed for same 
effect as GTP
Salomon et al. 
(1975)
XXXVII activation of adenyl 







XXXVII activation of adenyl 
cyclase (pigeon 
erythrocyte membrane)









held in activated 
state
Spiegel e£ a l . 
(1977)




Kuwano et al. 
(1969)
XXXVII Tubulin (bovine 
brain)^
does not bind 
XXXVII




Analogue System Effect Reference










does not replace 
GTP as stimulator
Raue & Cashel 
(1974)
XXXVII lamb brain tubulin 
production
no action Macconi & Seeds 
(1977)
6 . Analogues of other nucleotides
(i) Analogues of Uridine nucleotides
As one might expect, the nonisosteric analogue (XL) of 
UMP was found not to be a substrate for alkaline phosphatase from 
snake venom, bovine intestine, or E.coli (Holy, 1967). The





2 ^ 0 ^  U2 3
OH OH OH OH
XL XLI (U = Uridine)
incapable of polymerisation with polynucleotide phosphorylase from 
Micrococcus lysodeikticus (Yengoyan & Rammler, 1966).









of UDP-glucose to be a good substrate for bovine UDP-glucose 
dehydrogenase with a similar value to that of the natural substrate 
(12yM and 20yM respectively) but with a lower value (16% that of
the natural substrate). The analogue was, however a poor substrate 
for UDP-glucose phosphorylase being only 5% as effective as the 
natural substrate. Analogue XLII was not a substrate for UDP- 
galactose-4 epimerase.
Analogue XLIII was found to be without effect on 
thymidylate synthetase from E. coli, indicating a requirement for the 
dibasic acid for effective interaction (Holy & Vortruba, 1974) .
0












Wigler & Lozzio (1972) found that analogue XLIV 
(5 bromo, 2 ,deoxy-uridine 5 ’ methyl-phosphonate) a structural analogue 
of 2 deoxy-thymidine caused irreversible cytotoxicity to Chinese 
hamster cells. Nucleotides in general do not readily penetrate the 
membranes of living cells.but analogue XLIV even when fully ionized
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has only one negative charge and might accordingly get into the cell,
A  delay was in fact observed in the cytotoxic effect caused by 
analogue XLIV on the hamster cells consistent with time required 
for sufficient incorporation of the analogue into DNA to cause a lethal 
effect.
5-Fluorouracil is known to exert its cytotoxic action (and 
anti cancer effects) after conversion to 2 ’deoxy 5-fluoro uridylic 
acid (XLV) which inhibits thymidylate synthetase. Attempts to
N
( A  N /
P-O-CH^ ,0 HgO P-CH^ CH., _ 0
XLV XLV I
enhance this activity by the direct use of XLV have failed because 
of its rapid degradation to 5-fluorouracil. , Analogue LVI on the 
other hand should resist dephosphorylation and was accordingly studied 
by Montgomery et al, , (1979), XLVI was found to be a potent 
inhibitor of thymidylate synthetase from three individual sources, 
(Lactobacillus casei, E. coli and Coliphage T^) but nevertheless less 
potent than compound XLV, requiring preincubation with the enzyme. 
Analogue XLVI was moderately cytotoxic to H.Ep-2 cells in culture. .
(ii) Analogues of deoxy thymidine nucleotides
England e_t al^ . (1969) found that analogue XLVII bound to 
DNA polymerase from E . coli at the same site and with similar affinity 
to that of deoxy TTP (dissociation constants K = 130 and 80pM 
respectively). Further investigations (Geider, 1972), showed
—48—
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P-CH^-P-O-CH^ 0  T
OH
XLVIII
analogues XLVll and XLVIII to be neither substrates nor inhibitors 
of DNA polymerase in nucleotide—permeable E. coli cells, showing that 
although the phosphonate analogues might bind to DNA polymerase, 
subsequent steps in the polymerisation process cannot proceed.
Rammler et al. (1972) found that analogue XLIX was a 
weaker inhibiLor of micrococcal nuclease than was deoxy TMP (8 % and 
16% inhibition respectively). The authors suggested that the weaker
H^O^-P-CH. , 0
OH XLIX
inhibition observed for the nonisosteric analogue resulted from its 
smaller size.
(iii) Analogues of IMP
isosteric analogue ( L ) of IMP, like that of AMP 
(XXIV), was found to be a substrate for adenyl 0-succinate 
synthetase, (Table 15) (Hampton & Chu, 1970) suggesting that the
Table 15
Compound K pM 
m
V (Relative to IMP) 
max
IMP 2 0 1 . 0
h 160 0.035
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C-5 oxygen atom of IMP does not make a major contribution to the total 
binding energy of IMP in this system.
0




Nichol jet £ l . (1967), studying the phosphate-binding sites of 
inosinic acid dehydrogenase and adenylsuccinate synthetase (from E. Coli), 
investigated the effect of analogue LI, which was found not to be a 
substrate for either enzyme.
The above sections have outlined studies of mononucleotide 
analogues in which the structural changes largely involve replacement 
of CH^-O-P groupings by CH^-CH^-P or CH^-P moieties. Not only mono­
nucleotides but also dinucleotides (Griffin e^ a T ., 1973, and Johnson 
& Schleich, 1974) have been modified so as to produce phosphonate 
analogues, the properties of which have been studied. Moreover 
structural modification has not been confined to the basically simple
changes discussed above. For example C H - O - P  of the naturally-occurring
ÇL
compound has been substituted by CPL-CH_-P, CH — CH--P and C H -ÇH-P
CL NH^ CL
(Holy & Hong, 1971, 1972 and Gulyaev & Holy, 1972) and many other 
modifications have been reported.
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Other Phosphonate analogues
Diphosphonate analogues have been extensively investigated 
(and used clinically) showing similar properties to inorganic pyro­
phosphate with regard to calcium metabolism. (Review, Fleish et al., 
1977). Analogues of pyridoxalphosphate have also been investigated 
(Bennett jet , 1959, Hullar, 1967, and Vidgoff e£ al^., 1974) as 
have phosphonate analogues of intermediates of squalene biosynthesis 
and other terpenes. (Corey & Volante, 1976, and Sarin et al., 1977).
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(B) PHOSPHOLIPIDS
Since phosphonolipids were first demonstrated to occur 
naturally (Horiguchi & Kandatsu, 1959) there has been a great deal of 
interest in their organic synthesis and biological activity. They 
have been synthesised as reference compounds for elucidation of the 
structure and configuration of naturally-occurring phosphonolipids, 
for possible use as inhibitors of enzymes utilizing phospholipids 
and as potential analogues of phospholipids in biochemical investi­
gations generally. Apart from the phosphatidic acids, phospholipids 
are diesters and their phosphonate analogues may have a C - P linkage 
on either the base or the glycerol side of the molecule. When both 
are present the compound is classed as a phosphinate and although 
such compounds have so far not been found in nature they often show 
interesting biochemical properties.
1. Analogues of Phosphatidic Acids
Rosenthal & Pousada (1966) demonstrated that the diether
analogue (LIII) inhibited the particulate phosphatidate phosphatase
from pig kidney. The diether analogue LIII although nonisosteric
is a relatively close analogue of phosphatidic acids (LII) and the
reported inhibition might in isolation be regarded as the result of
0
II
CH^-O-C-R^ C H - O - R ^  C-R^
0 CH-0-R_ C-C H ~ P O „  H_
II I z I Z J z
CH-O-C-R^ C H - P O ^ H ^  ^"^2
CH^-O-PO^H^
LII LIII LIV
a specific enzyme-analogue interaction. However the stcrically
-52-
distinct phosphonate analogue LIV containing neither ester nor ether 
groups was found to be an equally powerful inhibitor of the same 
enzyme system, suggesting that inhibition in this case might result 
from relatively non-specific effects unrelated to the detailed 
structure of the inhibitor. Such indications are reinforced by the 
observation that the inhibition by phosphonate analogue LIII depended 
on the length of time of pre-incubation of the enzyme with the 
analogue and on the degree of dispersion of the latter, suggesting 
that physicochemical factors might be playing a role in the observed 
results.
Soluble pig kidney phosphatidate phosphatase was also 
inhibited by analogue LIII and, surprisingly, to a less extent by the 
isosteric diether analogue LV (Rosenthal & Han, 1968).
C H — 0-R-I 2 . 1
CH-0-R_
I '
C H - C H - P O ^ H ^
LV
Inhibition of the soluble enzyme was much less influenced by enzyme- 
analogue pre-incubation than in the case of the particulate system; 
a fact which further emphasises the possible involvement of physical 
factors in the latter enzyme and in enzyme-catalysed reactions of 
phospholipids generally.
As might be expected, phosphonate analogue LIII had no 
substrate activity for phospholipase C from Clostridium perfringens 
but was an inhibitor of this enzyme. However, inhibition was not 
competitive but was again found to result from physical factors.
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The fact that analogue LIII is negatively-charged means that it 
could act by altering the electro kinetic properties of the 
dispersed substrate particles or by binding calcium necessary for 
activity (Rosenthal & Pousada, 1968).
Rosenthal and his co-workers examined the effects of 
analogue LIII on in vivo systems. Only two out of thirteen species of 
bacteria tested were found to be significantly inhibited by the 
analogue (Rosenthal & Pousada, 1966). Intraperitoneal administration 
of the phosphonate analogue LIII into rats results in a reversible 
accumulation of triglycerides; an observation which was not easily 
related to the demonstrated inhibition of phosphatidate phosphatase 
(Rosenthal & Han, 1968). A  possible explanation could involve the 
interference of fat removal from the liver to the circulation by 
complexing of the phosphonate analogue LIII with transport apolipo- 
proteins.
The effect of phosphonate analogue LIII on an vitro
metabolic system was also examined. Addition of rat liver supernatant 
fraction to microsomal preparations led to stimulation of palmitic 
acid incorporation into triglycerides and this incorporation was 
inhibited by phosphonate analogue LIII (Rosenthal & Han, 1968). This 
inhibitory effect provides supporting evidence that the original 
stimulation of palmitic acid incorporation is the result of phosphatidate 
phosphatase present in the supernatant.
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2. Analogues of phosphatidylethanolamine
The nonisosteric (relative to the ethanolamine moiety) 
phosphonate analogue (LVI) of phosphatidylethanolamine was found not 
to be hydrolysed by phospholipase C from Clostridium welchii (Baer & 
Stanacev, 1966). However Rosenthal & Pousada (1968) showed that 
the phosphonate analogue LVI and two other phosphonate analogues of 
phosphatidylethalolamine were inhibitors of phospholipase C from 
Clostridium perfringens. The nonisosteric (in relation to the
CH-0 - C - C 3 3  H33
II +
C H ^ O - P  —  C H ^  C H ^ N H ^  
OH
^ ^ 2  ® ^18 H 3 7
CH-O-C 1 6  H 3 3
II +
C H ^ P - O - C H  -  C H - N H 3  
OH
CH 2  C^^ H 3 3
I 9 4“
C H - C H - P O  - C H - C H  -  NH 
I ^ ÔH ^ )
C H ^ C i 7 H 3 3
LVI LVII LVIII
glycerol moiety) diether phosphonate analogue LVII was a better 
inhibitor than the nonisosteric (in relation to the base moiety) fatty 
ester phosphonate LVI while the structurally-different branched-chain 
hydrocarbon phosphonate LVIII was the worst inhibitor. These phosr 
phonate analogues of phosphatidylethanolamine were poorer inhibitors 
than the corresponding phosphatidylcholine analogues which were also 
tested in the above system.
The isosteric diether phosphonate analogue LV (R^=R2 = 
C^g-H^y) was found to be an activator of phospholipase A from snake 
venom, (A.piscivorus) but this activation was demonstrated to be the
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result of a physical effect on the substrate lipoprotein (Rosenthal & 
Han, 1970).
3. Analogues of phosphatidylcholine
Baer & Stanacev (1966) demonstrated that, unlike the phos- 
phatidylethanolamine phosphonate analogue LVI the nonisosteric 
phosphonate analogue LIX was hydrolysed after several hours in the 
presence of phospholipase C from Clostridium welchii. Rosenthal & 
Pousada (1968), on the other hand demonstrated that compound LIX was 




CH O-C-C33 %31 
6
CH-O-C^g H 32 
; 0
CH -  C H - P —  0 - C H - C H ^ - N  (CH^)
ÙH- 0 -Cig H 3 3
0
C H ^ - O - P - C H - C H — N(CH 3 ) 3  
OH
OH
3" 3 C H ^ P - 0-CH^CH^N(CH3)3
OH
LIX LX LXI
no substrate activity after thirty minutes incubation with the enzyme. 
The most effective phosphonate analogue inhibitors in this system were 
found to be the isosteric (LX) and the nonisosteric (LXI) diether 
analogues in both of which a C - P bond links the phosphorus atom 
directly to the glycerol moiety. Phosphonate analogues LX and LXI 
gave relatively simple kinetics, displaying ordinary competitive 
inhibition, the isostere LX being a better inhibitor than the non- 
isostere LXI. Further to these studies Rosenthal & Chodsky (1974) 
investigated the relative inhibitions of phospholipase C by a series 
of diether phosphinates (LXII ->• LXV). Simple correlation between
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inhibitory activity and structure was not possible. For example none
CH 2 0 -C^g H 3 2
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of the phosphinate analogues LXII -> LXV was as strong an inhibitor as 
was the isosteric phosphonate analogue LX and the corresponding isosteric 
phosphinate analogue LXV was the worst. This might suggest that the 
oxygen atom of the choline moiety is important for inhibitory activity. 
However the nonisosteric phosphinate analogue LXII which lacks such an 
oxygen atom is a good inhibitor. It is likely that physicochemical 
properties such as particle size and detergent effect are of particular 
relevance in this enzyme system.
Studies on phospholipase A from snake venom (A. pescivorus) 
showed phosphinate analogue LXII to be a stronger inhibitor than either
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3
of the phosphonate analogues LX and LXI. In this system also, however 
physicochemical effects were found to dominate the interactions of the 
substrate analogues with the enzyme (Rosenthal & Han, 1970).
Bjerve (1972) demonstrated that the isosteric (LXVI) and the
nonisosteric (LXVIII) phosphonate analogues of choline phosphate
(LXVIII) were both incorporated into phosphatidylcholines in rat liver
+ + + 
H ^O gP-CH-CH-C H-NC CH^)^ H^OgP-CH^CH-N(CH3)  ^ H203P-Q-CH^CH2-N (C H3)3
LXVI LXVII LXVIII
and kidney v i v o . The phosphonate was incorporated as a unit,
utilizing the same pathway as that used by the natural substrate.
Subsequently excreted compounds were found to be unchanged, indicating
that the rat could not break down the C - P bond. Surprisingly, the
nonisosteric phosphonate analogue LXVII was a better substrate for
phosphocholine cytidyl transferase than was the isosteric phosphonate
analogue LXVI. Analogue LXVII was found to be a competitive
inhibitor of choline phosphate transfer (and vice versa). (Table 15).
Table 15




V relative to LXVIII 
max
LXVII 5.2 5.2 1
LXVIII 0.35 0.17 1
The biochemical properties of phosphatidylcholine analogues 
incorporated into artificial bilayer membranes have been extensively 
studied. When phosphonate analogue LXI replaced phosphatidylcholine 
in a phosphatidylcholine - phosphatidylserine-cholesterol(0.7 : 0.3 : 
1.0 w/w/w) bilayer membrane there was an inhibition of phospholipase C
—58-
action on the membrane (Hendrickson e_t a l ., 1974) . The degree of 
inhibition was proportional, over a wide range, to the percentage 
of analogue LXI that had been substituted for phosphatidylcholine, 
indicating that the inhibitory effect was non-specific. This is 
contrary to the inhibition of phospholipase C by the phosphonate LXI 
in aqueous dispersions (Rosenthal & Pousada, 1968) see page 55 .
Complete hydrolysis of the phosphatidylcholine in the bilayer membrane 
must involve reorganisation of the bilayer structure and/or penetration 
of the enzyme into the inner bilayers and it may be that these processes 
are inhibited by the presence of the phosphonate LXI.
The presence of cholesterol lowers the initial rate of water 
penetration to the same extent in diester and diether phosphatidyl­
choline-containing liposomes, suggesting that the carbonyl linkage has 
a negligible role in the packing of the lipids. Furthermore, liposomes 
made from the isosteric phosphonate (LX) or phosphinate (LXIV) 
analogues are affected by the presence of cholesterol similarly to 
liposomes containing the natural phosphatidylcholine. However liposomes 
made from the nonisosteric phosphonate(LXI) or phosphinate(LXIII) 
analogues displayed no interaction with cholesterol (Bittman & Blau, 
1972). This indicates that strict steric demands at the polar head 
must be met in order for a phosphatidylcholine-cholesterol complex to 
form and that stereoelectronic effects are of secondary importance.
In contrast DeKruyff e_t a l . (1973) demonstrated that liposomes made 
from a nonisosteric straight chain phosphonate LXIX displayed
0
II +




comparable behaviour to that of natural phosphatidylcholine lipo­
somes in the presence of cholesterol.
Kinsky et al. (1974) showed that sealed liposomes made from 
the nonisosteric phosphonate (LXX) and phosphinate (LXXI) analogues 
do not release labelled glucose in the presence of phospholipase C 
consistent with the findings (see page 55 ) that phosphonate and 
phosphinate analogues of phosphatidylcholine do not function as 
substrates for phospholipases. Liposomes made from LXX and LXXI, 
like those made from phosphatidylcholine were however lysed in the
0
CHf-O-C-Cij H 33 
0
CH-O-C-C^ H 3 3
ÇH 3- 0 -C 1 8  H 3 7  
CH- 0 -C3 8  H 3 3
0  C H ^ P - C f c C H - N  (CH.).
II 2 I . z 2  i J
C H . - P - O - C H - C H - N  (CH_)_ OH
Z I Z Z j  j
OH
LXX LXXI
presence of specific antibodies and complement. The authors inter­
preted these results as demonstrating that the complement-mediated 
lysis of liposomes (and by implication, of cell membranes) is not 
the direct result of phospholipase action.
4. Analogues of other phospholipids
The isosteric (LXXII) and the nonisosteric (LXXIII) phos­
phonate analogues of GDP diglyceride (LXXIV) were found to be 
substrates for GDP diglyceride: glycerol 3 phosphate phosphatidyl 
transferase and for GDP diglyceride: L serine phosphatidyl trans­
ferase (Tyhach et al., 1975). Both phosphonate analogues were
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good substrates for the former enzyme having similar kinetic parameters 
to those of the natural substrate CDP dipalmitin (LXXIV) (Table 16)..
CDP diglyceride L serine phosphatidyl transferase appeared to have a
Table 16
CDP diglyceride glycerol 3 CDP diglyceride:L serine









LXXII 80 1 0 . 8 0 . 1
LXXIII 60 1 0.4 0 . 1
LXXIV 44 1 1.4 1 . 0
stricter substrate requirement, and the fact that both analogues had 
the same value suggested either that the phosphonate group or the
ether groups were responsible for the low activity of these compounds.
— 61“
Increased hydrophobicity of LXXII and LXXIII may account for the
smaller K values that were obtained, 
m
The isosteric phosphonate analogue LXXV of lysophosphatidic 
acid (LXXVI) was a substrate for lysophosphatidic acid acyl
0 0
II  II
CH^ -O-C-Cis H3^  JH3-O-C-C33 H33
HOCH HOCH
I I
C H -C H -P O 3  H3 CH2-O-PO3 H3
LXXV LXXVI
transferase and was found to have a higher value (300yM) compared 
with that (50yM) for lysophosphatidic acid, indicative of a lower binding 
affinity of the analogue for the enzyme (Tang al^ . 1977) .
The nonisosteric phosphonate analogue LXXVII of sphinganine 
phosphate (LXXVIII) has been studied vivo and vitro (Stoffel &
Grol, 1974). The phosphonate analogue LXXVII was a substrate for the 
pyridoxyl phosphate lyase: aldolase having a similar value (16ymoles)
OH NH„ OH NH.
I I  I I
CH3- (CH3) Y  CH-CH-CH -P O  H CHr- (CH^) CH-CH-CHj- O-PO3H3
LXXVII LXXVIII
but a smaller V value (0.1) than those of the natural substrate 
max
(LXXVIII), and LXXVII was also found to be a competitive inhibitor of 
the aldolase (K^ = 5ymoles). When analogue LXXVII was intravenously 
injected into rats (2 ymoles) they died within one minute and 2 0 ymolar 
concentrations of the phosphonate analogue (LXXVII) were found to 




Comparatively little biochemical investigation has been 
reported to date on phosphonate analogues of carbohydrates,
1. Analogues of Hexoses
Griffin & Burger (1956) found that the nonisosteric phos­
phonate analogue LXXIX of glucose 6 -phosphate did not inhibit choline 
acetylase, histidine decarboxylase, xanthine oxidase or hyaluronidase. 
The ester derivative (LXXX) caused production of acetylcholine by 
choline acetylase in the absence of ATP and increased acetylcholine 
formation on addition of sub optimal amounts of ATP. The significance 
of these results is not clear.
0 
II
H O P  -  CH (C H^) 0 P-CH
LXXIX LXXX
The isosteric phosphonate analogue X of glucose 6  phosphate
was shown to be a good substrate for yeast glucose 6 phosphate 
dehydrogenase [Table 1^| (Adams e_t , 1976). The value of 
compound X did not significantly change on raising the pH from 7.5 
to 8 , 0  and it was concluded that the higher values obtained 
compared with those of glucose 6 -phosphate could not be explained in 
terms of differences in states of ionization. The lower affinity 
of glucose 6 -phosphate dehydrogenase for the analogue X compared to 
that for the natural substrate was suggested to result from other 
factors. It could be that the replacement of C-O-P in glucose 6 - 
phosphate by C-CH^-P in the analogue would lead to loss of inter­
action with the enzyme, either because the oxygen atom is necessary
-63-
Table 17. Comparison of kinetic parameters for glucose 6 -phosphate 
and its phosphonate analogue (X).




compound pH 7.5 pH 8.0 pH 7.5 pH 8.0 ^ pH 7.5 pH 8.0
glucose 6  
-phosphate
6-21 51 46 7.5 6 . 8 1 1
X 7*50 227 192 6 . 2 6.5 0.58 0.46
( Relative to glucose 6 -phosphate)
for binding or because of minor geometrical differences between the two 
structures. The product of enzymic dehydrogenation of analogue X was 
itself shown to be a substrate for yeast 6 phosphogluconate dehydro­
genase (Adams et al., 1976).
A  similar pattern of results was obtained (Stribling, 1974)
for the enzymically-prepared 1-phosphonomethyl isostere (LXXXl) of
fructose 1,6 bisphosphate (LXXXII) in its interaction with aldolase.
There was however an even larger decrease in the V value of LXXXI
max
H^O^P-O-CH . . 0
CH-CH-PO^H^ C H-O-PO^H^
H 0 P - C H - C H  0 O HX1 >|
O-PO^H^
O H  O H  O H
LXXXI LXXXII LXXXIII
compared to that of the natural substrate LXXXII (i.e. one twentieth •
that of LXXXII). As one might expect, analogue LXXXI showed no
measurable activity with fructose bisphosphatase and was a competitive
inhibitor of the natural substrate (K^ = 70|jM compared to = 4yM
for LXXXII).
More recently the 6 -phosphonomethyl isostere LXXXIII of 
fructose, 1 ,6 -bisphosphate has been enzymically-prepared and found to
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be a substrate for aldolase (Webster et al., 1976). Surprisingly
LXXXIII was, however, not a substrate for 1,6 bisphosphatase but was a
competitive inhibitor, with a K. value CL50yM) nearly two orders of
1
magnitude greater than the value of the natural substrate (LXXXII). 
The authors put forward two possible explanations for this:- that 
interaction between the oxygen normally present on C - 6  and some part 
of the enzyme is necessary before catalysis can occur or that 
analogue LXXXIII may bind the wrong way round so precluding catalysis. 
However analogue LXXXIII was found to be a substrate for the sequential 
actions of glucose 6 -phosphate isomerase, and glucose 6 -phosphate 
dehydrogenase, (the product of the isomerase reaction appeared to be a 
poor substrate for the dehydrogenase) confirming the work of Adams e^ a l , 
(1976).
Tang e^ al. (1978) recently reported the synthesis of the 
isosteric phosphonate analogue LXXXIV of fructose 1-phosphate. The 





that are capable of transporting hexose phosphates.
2. Analogues of Pentoses
Arabinose 5-phosphate (LXXXV) is a precursor in the bio­
synthesis of 3 deoxyoctulosonate (LXXXVI), a component present in 
lipopolysaccharide structures of all Gram-negative organisms. The 
first step involves condensation of the pentose LXXXV with phosphoenol- 
pyruvate catalysed by 3-deoxyoctulosonate 8 -phosphate synthetase to 
give 3 deoxyoctulosonate 8 -phosphatc (LXXXVII ) which in turn is
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dephosphorylated by a specific phosphatase to give LXXXVI . The 
isosteric analogue of arabinose 5-phosphate was found to be a
HO-CH^
HO-CH







substrate for 3-deoxyoctulosonate 8 -phosphate synthetase (Unger aj^., 
1978). The crude enzyme preparation used in these studies contained 
both the synthetase and the specific phosphatase but only limited 
formation of phosphonate LXXXIX was detected as concentrations of 
LXXXVIII were increased. It was suggested that the phosphonate inter-
H_0_ P-CH_-CH_ 
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mediate LXXXIX accumulated because it was not a substrate for the phos­
phatase and that product inhibition of the synthetase resulted. Such 
inhibition might provide a basis for the rational design of an anti­
bacterial agent.
The methylene isostere (XC) of 5-phosphoribosyl 
pyrophosphatate (PRPP) was isolated after the reaction of ribose 
5-phosphate and 0-adenyl methylene diphosphate (XVI) in the presence 
of phosphoribosyl pyrophosphate synthetase (from Erhlich ascites 
tumour cells) (Murray e^ al., 1969). This reaction clearly involves a 
transfer of the pyrophosphate analogue as a unit, and the transfer in 







Analogue XC was shown to be a substrate for three phosphoribosyl 
transferase enzymes (Table 18). The lower values, (compared to
those of the natural substrate) obtained for XC . with adenine and 
hypoxanthine transferases are thought to result partially from the 
lower electronegativity of the phosphonate analogue, as the reaction 
between the nucleotide and the sugar involves nucleophilic displace­
ment at the C-1 position of the sugar. Analogue XC was not 
recognised by 5-phosphoribosyl 1 pyrophosphate ami do transferase or 
oratate phosphoribosyl transferase (Murray ^  al., 1969).
Table 18




PRPP XC relative to PRPP
adenine phosphoribosyl transferase 13.2 2 . 2 0 . 0 1 1
hypoxanthine " " 23.0 4.3 0.26
nicotinamide " " 19.8 125.0 1 . 1
3. Analogues of other glycolytic intermediates
(i) Analogues of glycerol 3-phosphate
Phosphonate analogues of sn-glycerol 3-phosphate (XCI) 
have been extensively studied. Initial work with the nonisosteric 
analogue (XCII) was not promising, showing neither substrate nor 
inhibitory activity with rabbit muscle glycerol 3-phosphate dehydro-
—67“
genase (Baer ^  al^., 1969). However Cheng et^  a^. (1974) found that 
the isosteric analogue XCIII had similar kinetic parameters to that 
of glycerol 3-phosphate with rabbit muscle glycerol 3-phosphate 












Adams e^ al. (1974) who also demonstrated that the mono anionic me thy 1- 
phosphonate analogue XCIV and the nonisosteric hydroxymethyl phosphon­
ate analogue XCV were totally inert with glycerol 3-phosphate 
dehydrogenase. These results indicate that although the esterified
Table 19






glycerol 3-phosphate 0.24 0.16 0.066
XCIII 0.19 0 . 2 0 0.059
C-3 oxygen of sn-glycerol 3-phosphate has no major direct interaction 
with the enzyme, the spatial relationship of the carbon-3 atom to the 
phosphorus atom must approximate to that in the sn-glycerol 3-phosphate
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molecule for efficient binding to the enzyme and that substrates 
bind to the enzyme in their dianionic forms.
Cheng jet al. (1975) studied the ability of the E. coli 
enzymes involved in glycerol 3-phosphate metabolism to recognise the 
phosphonate analogues XCII and XCIII . sn-Glycerol 3-phosphate 
and the isosteric analogue XCIII were found to inhibit competitively 
the reduction of dihydroxyacetone phosphate by soluble glycerol 3- 
phosphate dehydrogenase (K^ values 19pN and 42yM respectively) whereas 
the nonisosteric analogue XCII (as could be predicted from the 
results with rabbit muscle glycerol 3-phosphate dehydrogenase) showed 
no inhibitory activity. Neither compound XCII nor XCIII showed 
substrate activity with membrane-bound glycerol 3-phosphate dehydro­
genase or with acyl glycerol phosphate acyltransferase. The isosteric 
analogue XCIII did not show any inhibitory activity with either of 
these enzymes. XCI was also without inhibitory effect upon the 
membrane-bound dehydrogenase but did appear slightly to inhibit the 
acyltransferase. Most importantly, XCIII was found to be a substrate 
(K^ = 450yM compared to sn-glycerol 3-phosphate value = 140yM) for 
glycerophosphate phosphatidyl transferase. Analogue XCIII did not 
effect phosphatidylserine synthase.
Since Kabak e^ al. (1972) demonstrated that the phosphonate 
XCIII is capable of inhibiting the growth of certain strains of 
E. Coli, the mechanism of this inhibition has been thoroughly studied.
It was demonstrated that XCIII is a bacteriostatic agent and that 
it differs in its action from that of the natural phosphate (which 
also inhibits the particular strains of E. Coli studied)(Shopsis et al., 
1972). Incorporation studies showed that analogue XCIII not only
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inhibits the uptake of labelled acetate into the lipid fraction of 
E. coli but also brings about a marked change in the distribution 
of the labelled acetate in the phospholipids (Shopsis et a l ., 1973). 
This altered composition of the phospholipids was quantified by 
Shopsis ejt a l . (1974) who used low concentrations of XCIII 
(SOymolar) in order to strongly inhibit phospholipid synthesis, while 
only mildly affecting cell growth. There was found to be a marked 
decrease in the cellular content of phosphatidyl glycerol which was 
shown to result from the inhibition of its synthesis (the rate of 
catabolism of phosphatidyl glycerol was unchanged). Phosphatidyl- 
ethanolamine and diphosphatidyl glycerol (cardiolipin) synthesis were 
both inhibited to a lesser extent. The fact that inhibition of phos- 
phatidylethanolamine synthesis was less marked and occurred later than 
phosphatidylj&ycerol synthesis suggested that this effect of compound 
XCIII is a secondary one. The observed lesser inhibition of syn­
thesis of diphosphatidyl glycerol compared to that of phosphatidyl 
glycerol itself may result from the preferential conversion of phos­
phatidyl glycerol into diphosphatidyl glycerol.
Cheng e^ (1975) postulated that the observed inhibition
of phosphatidyl glycerol synthesis in cells treated with XCIII is 
the result of a competition (observable vitro) of XCIII and 
glycerol 3-phosphate for glycerophosphate phosphatidyl transferase. 
[3 -^ 1^ -labelled XCIII has been incorporated into a polar lipid
material both by mutant strains of E. c6li and vitro by glycero­
phosphate phosphatidyl transferase (Tyhach et a l ., 1976). The product 
was identified as the isosteric phosphonate analogue of phosphatidyl 
glycerol 3-phosphoric acid (XCVI) which would not be expected to
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be enzymically converted to phosphatidyl glycerol. The appearance 
of such a phosphonate might have an effect upon membrane structure and
0
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function (as might also the decrease in cellular content of phosphatidyl- 
glycerol).
Analogue XCIII has been shown to be actively transported 
(reversibly) by the glycerol transport system of mutant strains of 
E. coli (Z. Leifer al_., 1977), with a value (200yMolar) 12 times 
larger (and a three times larger) than that of glycerol 3-phosphate.
The addition of cold glycerol 3-phosphate to E . coli cells incubated in 
the presence of [3-^H| labelled XCIII resulted in a decrease in the 
intracellular pool of labelled XCIII • Analogue XCIII also caused 
the release of intracellular glycerol 3-phosphate, and this exchange­
ability of XCIII , and glycerol 3-phosphate could cause depletion of 
intracellular glycerol 3-phosphate in cells cultured in the presence of 
XCIII . The resultant glycerol 3-phosphate starvation might explain 
observed effects of XCIII vivo, and the degradation of XCIII
in vivo may be the result of abnormal enzyme-substrate interactions 
resulting from elevated concentrations of XCIII.
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(ii) Analogues of Dihydroxyacetone Phosphate
The isosteric analogue XCVII of dihydroxyacetone phosphate 
XCVIII (like the isosteric analogue of glycerol 3-phosphate) has
C H - O H
I ^
C = 0
C H - C H - P O ^
C H - O H
I '
C = 0
CH 2- O - P O 3  H,
XCVII XCVIII
been shown to be a substrate for glycerol 3-phosphate dehydrogenase, 
with similar values to those of the natural substrate. Cheng et a l . 
(1974) studied the enzyme from rabbit muscle and found that XCVII 
although having a similar value, was reduced 25 times more slowly 
than the natural substrate (Table 20). Surprisingly the pH optimum for 
the analogue XCVII was lower than that of the natural substrate
Table 20






phosphate 0.13 2.9 0.61
XCVII 0.18 2 . 2 0.024
E. coli
Dihydroxyacetone 
phosphate. 0.4 1 . 0
XCVII 0.4 -- 0 . 1
which is not consistent with explanations of low analogue V values
max
in terms of high pKa. Similar results'were obtained by Stribling (1974) 
using E. coli as a source of glycerol 3-phosphate dehydrogenase (Table 20)
“7 2~
No significant differences in the ratio of V values at pH 7.2 and
max
pH 8.2 were observed for either the natural substrate or its analogue.
It is accordingly unlikely that the ionic form of the substrate is an
important factor in binding to the enzyme. The decrease in V
max
values for XCVII , like that of X for glucose 6 -phosphate dehydro­
genase and of LXXXI for aldolase can be attributed to very small 
changes in the geometry or to stereo electronic effects of the phosphate 
group, which has an essential role in catalysis.
In contrast, triose phosphate isomerases from chicken muscle 
or from Bacillus stearothermophilus showed no interaction with analogue 
XCVII (Dixon & Sparkes, 1974). The second pKa value of XCVII was 
found to differ by 1 . 1  units from that of dihydroxyacetone phosphate 
(7.1 and 6.0 respectively). If differences in interaction of XCVII 
and the natural substrate with triose phosphate isomerase were solely 
the result of a preference for a particular ionic form no more than a 
13 fold discrimination against XCVII could be achieved at any pH.
The total lack of substrate activity of XCVII could (could as in 
other cases) be expained on the basis that the enzyme normally inter­
acts with the C-O-P moiety. Alternatively Dixon & Sparkes suggested 
that the inactivity of XCVII may result from small geometrical 
differences (including the preference of the methylene group for the 
staggered conformation). This is a further example 
where substitution of a methylene group for oxygen prevents enzymic 
action even though the phosphate moiety is not directly involved in the 
catalysed reaction.
Analogue XCVII was shown to be incorporated into the cell 
wall of Bacillus subtilus when it acted as a bacteriocidal or bacterio-
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static agent depending on the strain used (Klein e^ , 1977).
(iii) Glyceraldehyde 3-phosphate
Goldstein ^  al^ . (1974) carried out ijn vitro and vivo







No kinetic parameters were determined, but racemic XCIX w a s  reported 
to be a substrate for rabbit muscle glyceraldehyde phosphate dehydro­
genase, and to totally inhibit growth of a mutant strain of E. coli.
The mechanism of this inhibition is unknown but glyceraldehyde 3-
phosphate has been shown to inhibit sn glycerol 3-phosphate transport,
and if the L form of XCIX were to enter the cell through this 
transport system it could interfere with cell metabolism. Conversion 
of the L-form into the D form might inhibit the glycolytic pathway.
Alternatively the L form itself could act as an inhibitor in other
pathways.
(iv) Analogues of Glycerate 3-phosphate
The isosteric analogue C was found to be a substrate for 
yeast phosphoglycerate kinase (Orr & Knowles, 1974). At pH 8.5 
both the analogue C and glycerate 3-phosphate itself (Cl) are essentially 
fully ionized and have similar K^ values. At pH 6.9, however, C was 
found to have a much larger K^ value compared to that of the natural 
















to the specificity of substrate binding for Glycerate 3-phosphate 
kinase is the electrostatic interaction between the dianionic 
phosphoryl groups of the substrate and one or more positively-charged
Table 21
pH pH 6.9 pH 8.5
substrate glycerate 3-phosphate C glycerate 3-phosphate C
K (mM) 
m
0 . 1 6.3 0.19 0.49
groups on the enzyme (in contrast to the situation found for other 
glycolytic enzymes mentioned so far).
No enzymic or antibacterial activity was observed for either 
of the analogues C and CII against several strains of Gram positive and 
Gram negative bacteria (Pfeiffer e^ a T ., 1974).
(v) Analogues of Glycerate 2,3-bisphosphate
The nonisosteric analogue G U I  was found to be incapable of 
replacing Glycerate 2,3-bisphosphate (CIV) as a regulator of the oxygen 
affinity of haemoglobin (Bensesch e^ , 1973) and it was concluded 
that the flexibility of the binding site is insufficient to adjust 
to the smaller and less acidic phosphonate. Pfeiffer ^  al. (1974) 
further demonstrated that neither the isosteric (CV) nor the non­
isosteric (cm) analogue had any effect on the oxygen dissociation 
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(vi). Analogues of phosphoenolpyruvate
The isosteric phosphonate analogue CVI of phosphoenol­
pyruvate CVII was found to be a substrate for rabbit muscle enolase and, 
as in the case of several other glycolytic enzymes, the values for
the phosphonate and natural phosphate were similar whereas the V
max
value of the phosphonate was substantially lower (Table 22) (Stubbe & 
Kenyon, 1972). Nowak et al. (1973) obtained similar results with yeast 
enolase. Not surprisingly the saturated analogue CVIII showed no
CH,










substrate activity with enolase.
CVIII
Table 22






Although Stubbe & Kenyon (1972) detected no substrate activity 
of phosphonate CVI with rabbit muscle pyruvate kinase, Reed & Cohn 
(1973) showed by electron paramagnetic resonance (EPR) that compound
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2+
CVI forms a ternary substrate - Mn - enzyme complex. The analogue- 
2+
Mn -enzyme ternary complex gave only an isotropic spectrum whereas
2+
the corresponding phosphoenolpyruvate -Mn -enzyme ternary complex 
displayed a superposition of spectra for two distinct species, one 
anisotropic and one isotropic. The latter matched the spectrum 
obtained for the analogue CVI ternary complex. Analogue CVI was found 
to bind more weakly to the enzyme than did phosphoenolpyruvate.
This allowed proton and paramagnetic relaxation studies which afforded 
quantitative structural information about the enzyme-analogue complexes. 
Further studies by James & Cohn (1974) demonstrated that analogue CVI 
competed with the natural substrate for the same binding site on the 
enzyme. They concluded that, although competition of an analogue and 
natural substrate for the same binding site, as demonstrated by kinetic 
or binding experiments, is a necessary condition for similarly- 
bonded enzyme complexes, it is by no means a sufficient condition. At 
least two other criteria must be met; the proton relaxation rates of 
water and EPR spectra should be similar for the natural substrate and 
the analogue before distances in the analogue-enzyme complex may be 
considered applicable to the natural substrate-enzyme complex.
Synthesis of 6,7 dideoxy a-D-gluco-heptose 
7-phosphonic acid, the isosteric phosphonate 
analogue of glucose- 6 -phosphate
- 7 7 -
Synthesis of phosphonate analogues of carbohydrate phosphates
Several approaches are now available for the introduction of 
a C-P bond into carbohydrates.
Griffin & Burger (1956) first reported the synthesis of a
phosphonate analogue of a naturally-occurring carbohydrate phosphate,
the nonisosteric analogue LXXIX of glucose 6 -phosphate. The phosphorus-
containing moiety was introduced into the protected 6 -bromo- 6 -deoxy-D-
glucose CIX by means of an Arbuzov reaction with diphenyl ethyl —
phosphite CX. Hydrogenolysis of the phenyl groups and hydrolysis of
the acetate ester groupings gave analogue LXXIX. The Arbuzov reaction
0
I ^ * ' ^ 2  P O 3 H 2
Ry rn CH
(Ph 0)2P(0Et) 2
°\i cx^  1/1 °\j(i)HypE
A e O # W l) A c  ™ _
OAc (ii) KOCH^/HOCH^
CIX LXXIX
of triethyl phosphite with compound CIX yielded the diethyl phosphonate 
ester of analogue LXXIX but all attempts to remove the ethyl esters by 
hydrolysis resulted in decomposition.
Any successful synthetic introduction of a phosphonate grouping 
necessarily involves the protection of the P-OH moiety by blocking groups 
which can be subsequently removed under mild conditions. Phenyl esters 
can sometimes, as above, be removed by hydrogenolysis but the reaction 
is unpredictable and often does not proceed. Benzyl esters are in 
general, readily removed by hydrogenolysis but the corresponding phos­
phites are difficult to prepare and use. Alkyl esters are stable and
—7 8—
easy to prepare but are not easily converted into the free acid. The 
conversion of the diethyl ester of analogue LXXIX to the free acid was 
claimed by Moffatt & Jones (1971) in a patent which reported heating 
the phosphonate diester to 150°C with sodium iodide in N.N-dime:thyl 
formamide (DMF) followed by treatment with aqueous acetic acid. The 
successful use of this technique was claimed for the synthesis of a 
series of isosteric and nonisosteric analogues of carbohydrates and 
other phosphates, although experimental details were presented for only 
a few systems (e.g. CXI and CXII the isosteric analogues of methyl 
riboside 5-phosphate and galactose 6 -phosphate respectively).
H 0 P-CH.-CH
H 0 P-CH -CH OCH H O / P - 0 _




An alternative, more convenient route for phosphorus intro­
duction involving the reaction of a stabilized Wittig reagent with an 
aldehydo group was claimed in another patent by Jones & Moffatt(1971 ).
The authors reported the use of this approach in the preparation of 
isosteric phosphonate analogues of D-xylose 5-phosphate,D-lyxose 5- 
phosphate, D-arabinose 5-phosphate, 2 deoxy D-ribose 5-phosphate, D- 
glucose 6 -phosphate and D-mannose 6 -phosphate. Again however, complete 
experimental details for each analogue were not given in the patent.
More recently Adams eJt aJ. (1976) have described the synthesis of the 
isosteric analogue of glucose 6 -phosphate (X)using the stabilised 
Wittig reagent of Jones & Moffatt(1971) . . This is described in the
Experimental and Results section (Scheme IB, pages 79-80) . Tang e^ £l. (1978) 
have prepared the isosteric analogue (LXXXIV) of fructose 1-phosphate








































































using a similar procedure (Scheme 2) which involves Pfitzner-Moffatt 
(Pfitzner & Moffatt 1965) oxidation of an unprotected alcohol grouping 
prior to reaction of the resulting aldehyde with the Wittig reagent. 
Unger ^  a l . (1978) in preparing the isosteric analogue (LXXXVlil)of 
aribinose 5-phosphate, again introduced the C-P bond by way of the 
Wittig reagent (diphenyl triphenylphosphoroanylidene-methylphosphonate) 
but generated the aldehydo precursor by use of pyridinium chlorochromate 
(Fetizon & Golfier, 1968) in preference to the Pfitzner Moffatt 
oxidation, which in their hands gave inferior yields.
Phosphonylation has been effected by the use of phosphite 
addition across activated olefinic linkages under both acidic (Paulsen & 
Thiem, 1973; Thiem ejt al., 1975) and basic (Paulsen eit al., 1971;
Paulsen & Greve, 1973) conditions in the preparation of various deoxy-, 
dehydro-, nitro- and amino deoxy phosphonocarbohydrate derivatives.
The reaction of 3,4,6-tri-0-acetyl-l,2-dideoxy hex-l-eno-pyranoses 
(glycals)(e.g. the arabino compound CXIII with dimethyl phosphite in 
the presence of BF^ gave dimethyl (4,6,-di-0-acetyl-2,3-dideoxy hex- 
2 enopyranosyl) phosphonates (CXIV + CXV) by way of an allylic arrange­
ment. Transestérification of the dimethyl esters to bis trimethyl silyl 
phosphonates led to the free phosphonic acids under very mild conditions
^ ' HOP(OMe)^ ÇH.OAc
OAc  ►
AcO I ' . AcO .
CXIII
CXIV (R^=H, R^ = P0(0Me)2) 50% 
CXV (R =PO(OMe)^ R^ = H) 50%
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Scheme 2
















(Paulsen & Thiem, 1973). Free phosphonic acids were not reported for 
the nitro and amino deoxyphosphonocarbohydrate derivatives.
The preparation of the nonisosteric phosphinate analogue (CXVI) 
of glucose 6 -phosphate has been reported (Kochemkov e^ aJ^., 1967) to 










Paulsen & Kuhne (1974) have synthesised the phosphonate CXVII 
in high yield by reaction of 2,3:4,5-di-0-isopropylidene-D-arabinose 






















Stribling (1974) prepared the 1-phosphonomethyl isostere 
(LXXXI) of fructose 1,6-bisphosphate (LXXXII) by way of the aldolase- 
catalysed condensation of 4-hydroxy 3 oxobutyl-l-phosphonic acid '
—84—
(XCVII) (the isosteric analogue of dihydroxyacetone phosphate),





CH^ OH aldolase H^ 0 ^ P-O-CH^
+ C=0




More recently Webster £t al^ . (1976) prepared the 6 -phosphono- 
methyl isostere (LXXXIII) of fructose 1,6-bisphosphate from the 
corresponding isosteric analogue (C) of glycerate 3-phosphate 
(Scheme 4).
Murray ^  al. (1969) prepared 5-phosphoribosyl 1-methylene 
diphosphonate (XC) the isosteric analogue of 5-phosphoribosyl pyro­
phosphate via the reaction of ribose 5-phosphate with the commercially- 
available isosteric phosphonic analogue of ATP (XVI) catalysed by
5-phosphoribosyl pyrophosphate synthetase from Ehrlich ascites- 
tumour cells.
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General - Melting points are uncorrected. Thin layer chromatography 
(t.l.c.) was performed on microscopic slides coated with silica gel G 
(Merck) and the chromatoplates were developed with 50% sulphuric acid 
or iodine vapour. Column chromatography was performed with silica gel 
(Merck) of particle size 0.063 0.2mM,mesh 70 230 ASTM. N.m.r.
spectra were measured with a Jeol-JNM4H-100 n.m.r. spectrometer at 
lOOmH with deuteriochloroform as solvent and tetramethylsilane as 
the internal standard. D line optical rotations was determined with 
a Bellinger and Stanley polarimeter, with a 1.0dm tube. IR spectra 
were measured with a Perkin-Elmer infrared spectrometer.
Solutions were concentrated under diminished pressure (rotary evaporator 
or vacuum pump) at bath temperatures below 40°C. Light petroleum refers 
to the fraction b.p. 60^-80°.
Benzyl 4,6-0-benzylidene-a-D-glycopyranoside flfl
This compound was prepared according to the procedure of •
Inch & Lewis (1972). A solution of D-glucose Q^| (800g) and toluene- 
p-sulphonic acid (40g) in benzyl alcohol (1500ml) was heated at 80°- 
100°C for 5 hr, cooled to 0°C and poured into an excess of ether (2&). 
The ether solution was stirred for 15 min and stored overnight at room 
temperature. The supernatant was then decanted from a syrupy residue 
which contained inter alia benzyl-a-D-glucopyranoside []^ | , detected 
by t.l.c. [Rf = 0 .2 , (benzene-methanol 1 2 :1 )J. Zinc chloride (500g) 
was added slowly to a solution of the syrupy residue in benzaldehyde 
(1500ml) which was stirred vigorously at room temperature for 3hr 
before being poured into a mixture of water (3£) and light petroleum 
(4&) and allowed to stand overnight at 5°C. The solid product was
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collected by filtration, (further crops were obtained by resuspension 
of the oily filtrate in water (32) and light petroleum (42) and storage 
overnight at 5°C prior to refiltration) dissolved in the minimal volume 
of hot ethanol (containing ammonia) and poured into an excess of water. 
The precipitate was removed by filtration and recrystallised from 
ethanol to afford benzyl 4,6-^-benzylidene-a-D-glucopyranoside (jf| (50g, 
yield 7%) the l.R. and n.m.r. spectra of which were identical to that 
previously obtained by Inch & Lewis (1972)[Rf 0.65, (chloroform-methanol 
1 2 :1 )1 1 .
Benzyl 2,3-di-0-benzyl-4,6-0-benzylidene-a-D-glucopyranoside [4|
Benzyl 4,6-0-benzylidene-a-D-glucopyranoside (50g) was 
added to a suspension of NaH (lOg) in dry ^  - dimethylformamide (500ml) 
at 10°C for 30 min. Benzyl chloride (50ml) was added dropwise to the 
stirred mixture, which was left to stand overnight at room temperature. 
Excess NaH was destroyed by addition of methanol (75ml) and the mixture 
was poured into water (32). The solid precipitate was removed by fil­
tration and recrystallized from methanol to give benzyl 2,3-di-O-benzyl- 
4,6-0-benzylidene a-D-glucopyranoside Q^| (4.5g, yield 60%) with 
identical l.R. and n.m.r. spectra to that previously obtained by 
Inch & Lewis (1972).
Benzyl 2,3,4-tri-O-benzyT-a-D-glucopyranosidc [5|
LiAlH^ (lOg) was added portionwise to a solution of the 
benzylidene acetal, [j^ | (40g) in dry ether (400ml) and dichloromethane 
(400ml). The mixture was heated under reflux in an atmosphere of N^, 
and a solution of AlCl^ (40g) in diethyl ether (400ml) was added drop- 
wise. The final mixture was boiled under reflux for S^hr. Excess of 
LiAlH^ in the cooled reaction mixture was decomposed by the sequential
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addition of ethyl acetate (10ml) and water (50ml) and the resultant 
precipitate (Al(OH)g) was removed hy filtration. The filtrate was 
concentrated leaving a residue which was recrystallised from petroleum 
ether to give benzyl 2,3,4-tri-O-benzyl-a-D-glucopyranoside 
(29g, yield 75.0%) with identical l.R. and n.m.r. spectra to that 
previously obtained by Adams (1976), [Rf 0.5 (light petroleum-
ether 1:3)3»
Benzyl 2,3,4-tri-O-benzyl-g-D-gluco-hexodialdo-1,5-pyranoside
Benzyl glycoside _5 (15g) in dimethylsulphoxide (150ml) was added 
slowly to a solution of dicyclohexylcarbodi-imide (30g) in benzene 
(150ml). Phosphoric acid (1.6ml) was added dropwise to the reaction 
mixture which was left to stand at room temperature. A white precip­
itate of dicyclohexylurea quickly formed and production of the alder 
hyde ^  was monitored by t.l.c. [kf 0.4 (light petroleum-ether, 1:3) 
cf 2  R f » 0 . .  After 15hr the reaction mixture was filtered (to remove 
the bulk of the dicyclohexylurea) and the filtrate was poured into a 
solution of oxalic acid (30g) in methanol (150ml). Sufficient diethyl 
ether was added to effect complete precipitation of salts which were 
removed by filtration and the filtrate was concentrated, poured into 
an aqueous solution of Na^CO^ and extracted with ether. The combined
ether extracts were washed once in water, dried ( MgSO^) and concen-
o
trated to give crude benzyl 2,3,4-tri-O-benzyl-a-D-gluco-hexdialdo- 
1,5-pyranoside, ^  (16g)(40% yield by n.m.r.) n.m.r. (chloroform-^) : 6 ,
9.6 (-CHO); 7.25 (0).
ITT
Benzyl 2,3,4, tri-O-benzyl-6 ,7 dideoxy-a-D-gluco-hept-6 -eno pyranoside, 
7-phosphonic acid diethyl ester Q J
Crude aldehyde ^  (16g) was used immediately without further 
purification, n-Butyl lithium (15ml) was added dropwise to a solution 
of tetraethyl , methylene diphosphonate 9_ (9g) in tetrahydrofuran (150ml) 
at -10°C. After 20 min the crude aldehyde ^  (17g) was added to the 
reaction mixture which was gently shaken and allowed to stand overnight 
under an atmosphere of at room temperature. Production of the diethyl 
phosphonate 2  0.3 (light petroleum-ether, 1:3)J was monitored by
t.l.c. and aliquots of n-butyl lithium were added until the reaction was 
complete. The completed reaction mixture was poured into water and 
extracted with ether. The ether extracts were combined, dried (MgSO^) 
and concentrated to give benzyl 2,3,4-tri-0-benzyl-6,7, dideoxy-a-D^- 
gluco-hept- 6 -eno pyranoside, 7-phosphonic acid diethyl ester Q } . The 
crude product was applied to a column of silica gel and eluted with 
light petroleum:ether (1:3). Fractions containing the product 2  
(monitored by t.l.c.) were collected and concentrated to give benzyl 
2,3,4-tri-0-benzyl-6,7-dideoxy-a-D-gluco hept- 6 -eno pyranoside, 7 
phosphonic acid diethyl ester Q _ |  (7 .Og)(yield 96%). N.m.r. (chloro­
form'd) : 6 , 7.3 (0); 6-7 (CH = CH); 4.1, 1.3 (OEt). I.R.: 8 .Op (P=0);
9.7 + 10.3p (P-OEt).
Benzyl 2,3,4 tri-O-benzyl 6,7 dideoxy q-D-gluco-hept- 6 -eno-pyranoside 
7 phosphonic acid [F]
Partially-purified diethyl ester 7_ (70g) was mixed with bromo- 
trimethylsilane 2 2  (2.3g, 1.5 mol.equiv.) and allowed to stand under 
an atmosphere of N^ overnight at room temperature. Disappearance of 
starting material 7_ Q.f 0.7 (ether)J was monitored by t.l.c. and after
—90—
15 hr aliquots of bromotrimethylsilane were added until starting 
material was completely absent. The reaction mixture was poured into 
a large excess of water (300ml) and acetone was added to obtain a 
homogeneous solution which was extracted with chloroform. The com­
bined chloroform extracts were dried (MgSO^) and concentrated to give 
a brown residue which was crystallized from benzene: light petroleum 
to give benzyl 2,3,4 tri-£ benzyl 6,7 dideoxy a D-gluco-
hept- 6 -eno-pyranoside 7-phosphonic acid [£| (3.55g yield 59%) mp 165- 
_  20 —
168 [aI D + 83.5 . N.m.r. (chloroform-^); 6 , 7.2 (0); 6-7 (HC=CH).
0
IR: 3-5y (P-OH).
6,7 dideoxy-a-D-gluco-heptose 7-phosphonic acid Q Q
A  solution of the unsaturated benzyl ether £  (3.4g) in 
ethanol (150ml) containing a few drops of trifluoroacetic acid was 
hydrogenolysed over 1 0 % palladium charcoal at room temperature and 
atmospheric pressure until hydrogen uptake ceased (uptake 700ml, 
theoretical value 653ml). The solution was filtered through Celite 
and concentrated to give 6,7 dideoxy-a-D-gluco-heptose 7-phosphonic 
acid (X)(1.3g yield 90%) as a hygroscopic white solid. Both n.m.r. 
and l.R. spectra showed the complete absence of benzyl groups, and 
were identical to the spectra obtained by Adams al^ . (1976)
The product X was dehydrogenated in the presence of NADP^ 
and yeast glucose 6 -phosphate dehydrogenase showing a K value (232mM)
m
identical to that obtained by Adams et al. (1976).
-91-
Tetraethyl methylene diphosphonate f^l
Tetraethyl methylene diphosphonate 9_ was prepared according 
to the procedure of Ford-More & Williams (1947) as modified by 
Kosolapoff (1953). Methylene iodide (20g) was added to triethyl 
phosphite (40g) and the temperature of the mixture was rapidly brought ; 
to 150°C by immersion in a preheated oil bath. Ethyl iodide (b.p. 
60-70°C) was allowed to distil from the reaction mixture which was 
then fractionally distilled under reduced pressure to give the 
following fractions: 60-70°C [diethyl methane phosphonate (85%) and 
diethyl iodomethane phosphonate (15%)J ; 70-120°C [diethyl iodomethane 
phosphonate (80%) and tetraethyl methylene diphosphonate (1 0 ) 1 5 ^ ;  
120-135°C [tetraethyl methylene diphosphonate (10)~| . N.m.r. (chloro- 
form-d): 6 , 2.4 (P-CH^-P); 4.2, 1.1 (OEt). IR: 7.95y (P = 0); 9.7,
10.3 (POEt).
Bromotrimethylsilane [IQ]
Bromotrimethylsilane was produced according to the procedure 
of Gilliam ^  al. (1946). Hexamethyldisiloxane (lOg), phosphorus 
tribromide (2 .8 g) and ferric chloride hexahydrate (60mg) were mixed 
thoroughly, sealed into a stoppered flask, and allowed to stand at room 
temperature for 48 hr. The reaction mixture was distilled under reduced 
pressure and bromotrimethylsilane 1£ was collected at 78°C.
n Butyl lithium
n-Butyl lithium was prepared from n-butyl bromide and lithium 
wire, and the concentration of the resulting solution was determined 
by hydrolysis and titration against HCl as described in Organic 
Reactions Vol. VI (ed. R. Adams e£ ^ . , 352-353) after the procedure' 
of Gilman et al. (1949).
— 9 2 —
DISCUSSION
A  synthesis of 6 ,7-dideoxy-a-D-gluco-heptose 7-phosphonate
(X) has been reported by Adams et a l . (1976) who followed Scheme lb.
This Scheme has two major disadvantages, the first of which concerns
the use of diphenyl triphenylphosphororanylidene^methylphosphonate
(11). This reagent is prepared by reaction of triphenylphosphine with
diphenyl chloromethylphosphonate to give a quaternary salt which can
be converted by base to the ylid. Thus:-
0 0 
« (t) I (.)
Ph P + CL CH - P  (0 Ph) — ►  Ph P CH - P  (0 Ph) Cl^ V
0 0
( + ) ( - )  II II
[Ph P-CH P (OPh) ^ ---> Ph P =  CHP (OPh) J
The reaction involving unreactive triphenylphosphine, presents a number 
of difficulties and the synthesis of diphenyl chloromethylphosphonate 
itself is not straightforward. The second major problem with Scheme lb 
concerns the removal of the phenyl groups from the ester 1 2 . give the 
phosphonic acid X. Phenyl ester groupings can occasionally (e.g.
h
Adams at al., 1974) be removed directly!hydrogenolysis but this 
reaction is unpredictable and Adams at al^ . (1976) were obliged to trans- 
esterify the phenyl ester (12) in 48% yield to the dibenzyl ester (13) 
which was then hydrogenolysed under mild conditions.
An alternative route to the glucose 6 -phosphate analogue(X)_ .
was accordingly investigated in the presently-described work. In view 
of the problems involved in the use of phenyl ester blocking groups it 
would be preferable to use the more easily-prepared and stable alkyl 
esters. These are, however, traditionally difficult to remove but in 
1977 McKenna et al. reported a facile dealkylation procedure using bromo-
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trimethylsilane and it was decided to make use of this reaction in the 
synthesis of phosphonate X.
The first five steps of the synthetic sequence were followed 
essentially as described by Adams ^  al^ . (1976) with only minor modi­
fications. Crystalline benzyl 4,6-0-benzylidene-a-D-glucopyranoside (_3) 
was obtained in low yield from ^ -glucose by direct benzylidination of 
a crude benzyl-a-D-glucopyranoside preparation as described by Inch & 
Lewis (1972). Further benzylation of the acetal 2  under standard 
conditions afforded benzyl 2,3-0^-benzyl-4,6-0-benzylidene-a-D-gluco- 
pyranoside (^), the acetal ring of which was cleaved by using 
LiAlH^/AlClg (Liptak e^ a l ., 1975) to give a high yield (75%) of 
crystalline benzyl 2,3,4-tri-O-benzyl-a-D-glucopyranoside (_5) . The 
primary alcohol _5 was now oxidised to the free aldehyde ^  by the 
procedure of Pfitzner & Moffat (1965). Adams e^ a l . (1976) did not 
attempt to isolate the aldehyde ^  but allowed it to react immediately 
with the ylid as described above in Scheme lb. Attempts were made 
in the present work to purify the intermediate ^  both by column 
chromatography on silica gel and by extraction in aqueous metabi­
sulphite solution. Neither method was successful and so the free 
aldehyde was allowed to react directly with the stable Wittig reagent 
tetraethyl methylene diphosphonate (^) . This reagent had been used 
by Albrecht e_t ad^ . (1970) in the conversion of 1,2:5, 6 -di-O-isopropy- 
lidene-a-D-.ribohexofuranose-3-ulose CXIX to the vinyl phosphate ester 
(CXX), and in the present work was found to be effective in converting 
aldehyde ^  into the diethyl phosphonate 7_ which was purified on a 
column of silica gel. As was hoped, compound 7 could be readily 







acid ^  which was readily debenzylated over palladium/charcoal at 
atmospheric pressure and room temperature to give the requirdd 
product X.
The overall yield of the final product X from benzyl 2,3,4- 
tri-O-benzyl-a-D-glucopyranoside ^  quoted by Adams et. JlL* (1976) was 
14%. The alternative synthesis of analogue X described here was 
done twice with overall yields from intermediate 2  23% and 17%.
The alternative synthesis of phosphonate analogue X (Scheme la) 
offers a number of advantages over that described by Adams (1976):
the Wittig reagent and the diethyl phosphonate 1_ are more easily 
prepared and stable than the corresponding intermediates in Scheme lb 
while preparation of the free acid from _7 proceeds reliably under mild 
conditions; the overall yield is better and could undoubtedly be 
improved, minor modifications of reaction conditions, work-up procedures, 
etc.; finally the overall synthesis of compound X from 2  is relatively 
rapid taking, in the second run, only 7 days.
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The two batches of phosphonate Analogue X prepared by the 
above method were homogeneous, with the same I.R. and n.m.r. spectra 
as those of the material prepared previously by Adams e_t (1976) 
and showed kinetic parameters identical with those of the latter 
product when examined as a substrate for yeast glucose 6 -phosphate 
dehydrogenase.
6,7 Dideoxy-g-D-gluco-heptose 7-phosphonic 




The synthesis of 6,7 dideoxy-a-D-gluco-heptose 7-phosphonic 
acid (X) has been described earlier. In this compound the C-O-P 
moiety of glucose 6 -phosphate is replaced by a C-CH^-P grouping and 
the analogue might be expected to mimic glucose 6 -phosphate in acting 
as a product inhibitor of brain hexokinase. This should clarify the 
nature of the contribution of the C - 6  oxygen atom of glucose 6 - 
phosphate to binding of the phosphate to hexokinase. This section of 
the thesis describes the purification of bovine brain hexokinase I 
(after the procedure of Redkar & Kenkare, 1972) and a comparative 
study of the activities of glutose 6 -phosphate and 6,7 dideoxy-a-D- 
gluco-heptose 7-phosphonic acid as product inhibitors of the purified 
enzyme.
Early studies by Weil-Malherbe & Bone (1951) demonstrated
that a feature of the regulation of mammalian hexokinases was the
potent inhibition of the reaction by the product glucose 6 -phosphate.
Crane & Sols (1954) reported the sugar phosphate product to be a
2-
noncompetitive inhibitor of both substrates (glucose and MgATP ) and 
postulated that the observed inhibition was the result of action at 
a regulatory site discrete from the catalytic site. This view was 
one of the earliest expressions of the concept of allosteric control. 
However, the question of whether glucose 6 -phosphate is a classical 
allosteric inhibitor or a normal product inhibitor is still in debate 
(Colowick, 1973; Casazza & Fromm, 1976; Wilson, 1978, 1979).
The original basis for the proposal of a separate regulatory 
site (Crane & Sols, 1954) was based on the observation that the con- ■ 
figurational and hydroxy 1 -group requirements of the hexose ring were
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different for substrate activity on the one hand or for product 
inhibitory activity on the other (Figure 1 ) (Crane & Sols 1954)
Substrate Inhibitor
• CH^-O-PO^H^CH.OH
Figure 1 • represents in each case the configuration or hydroxyl- 
group requirement for the specified activity.
suggesting discrete sites of different specificity for the substrate 
(glucose) and the inhibitor (glucose 6 -phosphate). Further evidence 
(Rose & Warms, 1967) showed that glucose 6 -phosphate has the special 
effect of solubilizing the enzyme and (Redkar & Kenkare, 1972) that 
glucose 6 -phosphate causes marked conformational changes as measured 
by sedimentation and protection of the enzyme against Ellman*s reagent, 
again indicating that the inhibition by glucose 6 -phosphate is effected 
at a discrete regulatory site. The fact that analogous inhibition 
(by glucose 6 -phosphate) is not seen with yeast hexokinase also suggests 
evolution of a special regulatory site.
As pointed out by Colowick (1973) and Wilson (1978) while 
this argument for a specific allosteric regulatory site is "compelling" 
it is by no means definitive. Fromm and his colleagues have, on the 
basis of binding and kinetic studies, consistently maintained that 
there is no discrete regulatory site for glucose 6 -phosphate 
(Purich et a l ., 1973% Ellison ^  al^., 1975a,b; Casazza & Fromm,
1976) and that the inhibition is the result of binding at, or over­
lapping the active site. From binding studies, Ellison e^ aT. (1975a)
— 98—
showed that there is only one glucose 6 -phosphate binding site per 
molecule of enzyme and that the kinetics of inhibition are not 
sigmoidal. Furthermore glucose has been shown to encourage the 
dissociation of glucose 6 -phosphate. The fact that an enzyme-glucose- 
glucose 6 -phosphate ternary complex forms indicates that the hexose 
rings of glucose and of glucose 6 -phosphate must bind to separate 
sites and this would explain the results of differing specificity for 
glucose and glucose 6 -phosphate binding sites (Crane & Sols, 1954).
These results and the fact that a number of workers have shown that 
glucose 6 -phosphate is a linear competitive inhibitor of ATP and a 
linear noncompetitive inhibitor of glucose (Fromm & Zewe, 1962;
Grossbard & Schimke, 1966; Kosow e_t £ l ., 1973; Gerber £t , 1974; 
Casazza & Fromm, 1976) for mammalian hexokinase led Casazza & Fromm 
(1976) to propose the following model for the mechanism of action of 
glucose 6 -phosphate inhibition of mammalian hexokinase. After phos­
phorylation of glucose to glucose 6 -phosphate the C-2 hydroxyl group 
becomes bound to the enzyme, at a site distinct from the glucose 
binding site, and in so doing permits the binding of a molecule of 
glucose. The phosphate moiety of glucose 6 -phosphate remains anchored 
to the y-phosphoryl portion of the ATP pocket during this sequence of 
events and serves to explain why glucose 6 -phosphate is a linear 
competitive product inhibitor of ATP. This proposed mechanism would 
seem to exclude a distinct allosteric site for glucose 6 -phosphate.
Wilson (1978) in proposing an overall mechanism of action for mammalian 
hexokinase adopted the same view.
Regardless of the question of the site of action of glucose
6 -phosphate, its importance as a regulator of the action of the mammalian
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hexokinases is not in doubt and the finer details of the mechanism 




Glucose 6 -phosphate dehydrogenase (yeast, grade II)
(EC. 1.1.1.49), glucose oxidase (fungal)(EC 1.1.3.4), peroxidase 
(horse-radish)(EC 1.11.1.7), pyruvate kinase/lactate dehydrogenase 
(rabbit muscle)(EC 2.7.1.40/EC 1.1.1.27), 3' phosphodiesterase (calf 
spleen)(EC 3.1.4.18), 5* phosphodiesterase (snake venom)(EC 3.1.4.1.), 
glucose 6 -phosphate, phosphoenolpyruvate, NADP^^ NADH and ATP were 
purchased from Boehringer Corp. (London) Ltd., London, W.5., U.K. 
n-Octonal was purchased from Koch-Light Laboratories Ltd., Colnbrook, 
Buck., U.K. Bovine serum albumin (used as a standard for measurement 
of protein concentration) O^dianisidine dihydrochloride and 2'- 
deoxythymidine-3-p-nitrophenol phosphate were obtained from Sigma 
Chemical Co. Ltd., London, U.K. DE52 DEAE cellulose was purchased 
from Whatman Ltd., Kent, U.K. All other chemicals were from 
BDH Chemicals, Poole, Dorset, U.K.
Beef brains from freshly-killed animals were obtained from 
Bristol slaughterhouse and immediately chilled on ice.
All spectrophotometric determinations were done using a
Unicam SP 1800 spectrophotometer at 25°C and all centrifugations
were carried out using an MSE 18 centrifuge. MgCl^.èH^O solution was
2+
titrated against O.IM, EDTA and the titrated value of Mg was found 
to be 100% pure by weight (Vogel p434).
Buffer A : lOmM-potassium phosphate, pH 7.0, containing 
5mM"EDTA, 5mM-mercaptoethanol and lOmM-glucose.
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Measurement of hexokinase activity during the purification procedure 
Hexokinase activity was measured by coupling the formation 
of glucose 6 -phosphate to the reduction of NADP^in the presence of 
glucose 6 -phosphate dehydrogenase and by measuring the increase in 
absorbance at 340nm. Reaction mixtures contained 0.16mM-NADl^, 6 mM-ATP, 
SmM-MgCl^, 27mM-glucose, 5iiiM- mercaptoethanol, glucose 6 -phosphate 
dehydrogenase (0.5 lu) and varying concentrations of enzyme sample in 
lOOmM-Tris-HCl buffer adjusted to pH 7.5 with 2M-NaOH (total volume 
3.015-3.11ml). Reactions were carried out in 1cm path length quartz 
cuvettes and were routinely started by addition of enzyme (5yl-100yl). 
Control experiments were done to ensure that the rate-limiting step 
was that catalysed by hexokinase.
Inhibition of hexokinase by glucose 6 -phosphate or 6,7 dideoxy-a-^- 
gluco-heptose 7-phosphonic acid
The initial rates of enzyme reactions were followed by
coupling the rate of ADP formation to the oxidation of NADH, using
phosphoenolpyruvate, pyruvate kinase and lactate dehydrogenase. The
assay system was essentially that developed by Ureta (1976) and measures
the decrease in absorbance at 340nm. Reaction mixtures contained,
13mM-NADH, 2.5mM-phosphoenolpyruvate, lactate dehydrogenase (11 I.U.),
pyruvate kinase (12 I.U.) and varying concentrations of substrates and
inhibitors in lOOmM-Tris HCl adjusted to pH 7.5 with 2M-NaOH (total
2+
volume 3.0ml). The concentration of Mg was adjusted in each case 
according to the ATP concentration so that ImM-free divalent ion was 
always present. 0.04 units purified bovine brain hexokinase I (0.04 I.U.) 
was added to start the reaction. Control experiments were carried out 
to ensure that the rate-limiting step was that catalysed by hexokinase 
and also that glucose 6 -phosphate and its isosteric phosphonate analogue
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had no effect on the coupling enzymes. One unit of hexokinase activity 
is defined as that amount of enzyme catalysing the transformation of 
lymole of glucose/min at 25°C. Specific activity is defined as units/ 
mg of protein.
Determination of glucose 6 -phosphate and 6,7 dideoxy-a-D-gluco- 
heptose 7-phosphonic acid (X)
Glucose 6 -phosphate (or analogue X) was measured by the amount 
+
of excess NADP (at least 10 times the concentration of glucose 6 -phosphate) 
that was reduced in the presence of glucose 6 -phosphate dehydrogenase, 
as shown by total increase in absorbance at 340nM. Reaction mixtures 
contained 0.8mM-NADP, glucose 6 -phosphate dehydrogenase (1.4 U.I.) and 
approximately 0.05-mM glucose 6 -phosphate (or analogue X) in lOOmM-Tris- 
HCl buffer adjusted to pH 7.5 with 2M-NaOH (total volume 1.22ml).
Reactions were started by addition of enzyme.
NADP^concentration was determined in an analogous manner, with
a reaction mixture containing 1 0  times excess of glucose 6 -phosphate in
+
relation to the NADP concentration.
value of 6,7 dideoxy-a-D-gluco-heptose, 7-phosphonic acid as substrate 
for yeast glucose 6 -phosphate dehydrogenase
Initial rates of enzyme reactions were followed by monitoring 
the reduction of NADP as shown by increase in absorbance at 340nm in the 
presence of glucose 6 -phosphate dehydrogenase. Reaction mixtures contained 
0 . 5inM-NADP, glucose 6 -phosphate dehydrogenase (0.7 I.U.) and varying 
concentrations (0.lmM-1.OmM) of 6,7 dideoxy-a-D-gluco-heptose, 7-phos­
phonic acid (X) in lOOmM-Tris-HCl adjusted to pH 7.5 with NaOH (total 
volume 1.005ml).
— 103~
Tests for phosphodiesterase activity
A. 3' nucleotidohydrolases
Phosphodiesterase activity was followed by measuring formation 
of p-nitrophenol resulting from the hydrolysis of 2 ’deoxythymidine-3’
,p-nitrophenol phosphate. Reaction mixtures contained 3mM-2' deoxy- 
thymidine-3'-p-nitrophenol phosphate and varying concentrations of 
enzyme in 650mM-citrate buffer (650mM trisodium citrate adjusted to 
pH 6.0 with 650mM-citric acid)(total volume 0.1ml). The reaction mixture 
was incubated for 5 min. before addition of O.lM-NaOH (2.9ml). The 
absorbance at 405nm was read against a control solution lacking enzyme.
B. 5* nucleotidohydrolases
Phosphodiesterase activity was followed by measuring formation 
of p-nitrophenol resulting from the hydrolysis of bis ^p-nitrophenol 
phosphate essentially as described above. Reaction mixtures contained 
bis-p-nitrophenyl phosphate (3.3mg/ml) and enzyme sample (20yl) in
0.2MTris-base buffer adjusted to pH 8.9 with IMHCI (total volume 3.0ml). 
The reaction was initiated by addition of enzyme.
Determination of glucose (glucose oxidase/peroxidase assay)
Glucose was measured by following the oxidation of ^  
dianisidine dihydrochloride via hydrogen peroxide in the presence of 
glucose oxidase and peroxidase. Reaction mixtures contained glucose 
solution (1ml), solution A [containing, glucose oxidase (0.333g), 
peroxidase (5mg), o^-dianisidine dihydrochloride (20mg) in 500mM 
sodium phosphate buffer, pH 7.0 (1 0 0 ml)J . The reaction mixture was 
incubated for 30 min at 25°C before addition of 60% H^SO^ (10ml) and 
reading the absorbance at 530nm.
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Protein determinations
Enzyme elution from DEAE cellulose columns during enzyme 
purification was monitored by the spectrophotometric procedure of 
Warburg & Christian (1941). Otherwise protein concentrations were 
determined by the method of Lowry e_t (1951) .
Values of K and V were obtained by extrapolation to 
m  max
infinite concentration of alternate susbstrate as described by 
Florini & Vestling (1957), by using, slopes from [^| /Vo versus [^| 
plots which were calculated by weighted regression (assuming simple error 
see page 113) using a computer programme based on the procedure 
described by Cornish”Bowden (1976),
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EXPERIMENTAL, RESULTS, AND DISCUSSION
Purification of bovine brain mitochondrial hexokinase isoenzyme type I 
Extraction and purification of bovine brain mitochondrial 
hexokinase was based on the procedure published by Redkar & Kenkare 
(1972). Unless otherwise indicated all steps were carried out at
0-4°C. Table 23 summarises the yields and specific activities 
throughout the procedure.
1. Homogenate and combined supernatants
Cortical tissue was carefully scraped from the white myelin 
of the brain of a freshly-killed cow and kept on ice overnight. Cortical 
tissue (150g) was suspended in 250mM-sucrose (750ml) containing 5mM- 
EDTA and several drops of n-octanol. The suspension was homogenised 
( 3 x 1  min) in a Braun homogeniser at maximum speed and the homogenate
(A) was centrifuged (800 10 m in). The resulting supernatant (B^)
was separated and stored and the pellet was resuspended in 250mM- 
sucrose (500ml), containing 5mM-EDTA and rehomogenised (1 min) before 
centrifugation (800 10 m i n ) . The sediment was discarded and the
supernatant (B^) was combined with supernatant B^.
2. Mitochondrial fraction
The combined supernatant fractions (B^ and B^) (1160ml) were 
centrifuged (13,000 15 min) and the mitochondrial pellet was dis­
persed (ultra Turex homogeniser) in buffer A (450ml) containing lOOmM- 
NaCl and centrifuged (13,000 gy 10 min). The supernatant was discarded. 
The mitochondrial pellet was resuspended in buffer A (150ml) and mixed 
with an equal volume of 50% (v/v) glycerol in Buffer A. The sus­
pension was dispersed (ultra Turex homogeniser,  ^ speed, 30 sec.) 
stirred for 15 min, and centrifuged (13,000 g, 30 m i n ) . The pellet
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in 25% (v/v) glycerol in buffer A  (150ml) was dispersed (ultra Turex) 
and centrifuged as before. The pellet was dispersed in 0.2M-sodium 
acetate buffer, pH 5.0 (268ml), containing 5mM-EDTA, 5mM-mercaptoethanol, 
lOmM-glucose and 900mM NaCl,
3. Acetate extract
The mitochondrial suspension (268ml) was stirred for 2 hr and 
dialysed overnight against 0.2M sodium acetate buffer, pH 8.0 (5&) 
containing 5mM-EDTA, 5mM-mercaptoethanol, lOmM-glucose and 900mM-NaCl.
The non-diffusible material was then further dialysed for 4 hr against 
the same buffer but lacking NaCl, stirred for I 5 hr. and centrifuged 
(20,000 30 min ) . The pellet was discarded and the supernatant was
adjusted to pH 7.0 with 8-80 liquor ammonia. The neutralised acetate 
extract (390ml) was turbid in appearance.
4. (NH^)2 S0 ^ fraction
(NH^)2 S0 ^ was added in small quantities with constant stirring 
to the neutralised acetate extract, (390ml) to 45% saturation 
(0.264 g/ml, total addition 103 g ) . During the addition the pH of the 
solution was maintained at approximately pH 7.0 by addition of 
ammonium hydroxide. After 30 min. a cloudy suspension formed which 
was removed by centrifugation (16,000 g, 15 min). The supernatant 
solution was adjusted to 70% (NH^)2 S0 ^ saturation (0.159 g/ml, total 
addition 62.01 g) by stepwise addition of (NH^)2 S0 ^ as before. The 
solution was allowed to stand for 30 min, centrifuged (16,000 g,
15 min.) and the supernatant was discarded. The pellet was resuspended 
in buffer A (25ml) and dialysed overnight against the same buffer (2jl).
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5. First DEAE - cellulose column
The dialysed (NH^)2 S0 ^ fraction (26ml) was applied to a 
DEAE-cellulose column (2.1 cm x  41 cm; preirequilibrated with buffer A), 
The column was eluted with buffer A  containing lOOmM-KCl with a flow 
rate 60 ml/hr maintained by using an LKB peristaltic pump. Fractions 
(5ml) were collected and assayed for protein and hexokinase activity.
Most of the inactive protein emerged from the column in the 
first column volume of the eluting buffer and the hexokinase was eluted 
immediately afterwards (see Figure 2).
Hexokinase-active fractions (25-32 inclusive) were combined 
(43.5ml) and purified by addition of (NH^)2 S0 ^ to 45% and then 70% 
saturation exactly as described above except that the precipitate was 
allowed to stand for 1 hr (instead of 30 min) in 70% saturated (NH^)2 S0 ^ 
before centrifugation. The precipiate obtained between 45% and 70% 
saturation with (NH^)2 S0 ^ was taken up in buffer A (16ml) and dialysed 
overnight against buffer A  (1&).
6 . Second DEAE cellulose column
The dialysed solution (18ml) obtained from 45%-70% (NH^)2 S0 ^ 
precipitation of hexokinase-active fractions from the first DEAE- 
cellulose column was immediately applied to a second DEAE-cellulose 
column (1.5cm x 18.5cm pre-equilibrated with buffer A). The elution 
was effected with a linear gradient of 0-120mM-KCl in Buffer A 
(200ml) with a flow rate 22ml/hr. Fractions (5.5ml) were collected 
and assayed for protein and hexokinase activity. The enzyme was 
eluted from the column with 4-8 column volumes of eluant, the peak of 
enzyme activity emerging at 35mH-KCl (Figure 3). Fractions 25 to 40 
(inclusive) were combined and subjected to (NH^)2 S0 ^ fractionation as
•108-
described in step 5. The 45%-70% (NH^)2 S0 ^ precipitate was taken up in 
buffer A (12.5ml) diluted with doubly-distilled water (12.5ml) and 





1— 1 <U •H 81-4
CSJ 0 0m COuO ONCO CM 0 01—4
CJ•H
0 )4-JOUa,a O uo O Ô O•H -P bO o 1—4 CO CO uo o om -H a•H > ^ o o o p 'd- CO COO *H • uo 0 0(U PA O •W <! M
rP NO O o oTD
1—i o (N vO CM CO (3N ON
0 ) o r-. m tP•H rP
C•H(UPOUÇU fO m COCJ Csl -d" NO•H P Ù0 O 1— 1 iP m uo O o‘p -H a•H > O o O CM r—1 COÜ *H • CM0) P04 O •CO <J M
Ï3
0 ) MWCtJ >» 0 0C P•H *H 1^ r'. uo P O ONr-l A: > o ON iP 0 0 UO OCj O -H 1— 1 UO m p iPp X P Ipo Q) aH ts <:
CMc St•H o O 0 0 -d" <N CO p ONip Q) o 0 0 tP CO P(d P CN CO NO CM NO COp o ON COO M bO lO v£> CO Q)H PM a iP P3
0) d(Uo O 0 0 o NO 0 0 or— 1 o NO NO CJN CM P CMO rP o\ iP CM CO o3>  a 1— 1 PCd
0 )P3 pîîCO o CUp •H 0 ) Æ CO Xi XC P C3 CO p. O PUcd O O o cd p  cdp Cd •H r-4 %4 0 P t)cd P P 0 bO P bO Q)04 C3 ip p O 1— 1 o P  O 53
0 ) p o cd p  p 0) P COp OJ p cd p CD cd O cd •H
w 04 cd p cp u a 1—4
0 •H p 1 o W O XC3 Q) CO p W  P <  P d
o P tJ CD O <3 rC M  X Oi•H (d T3 a CO w  o O Üp 0 0) o 0) A CO(d 0) a P CM Tl d po bO •H u cd P  ^ d a p•H o rQ o p w  0 o d d
(P a a p (U X P P CJ 1—1 CO•H o o •H u g •H O <u o 0 )M 53 u S <3 (P  O CO o p
s iP CM CO uo NO r~. 4(



































F r a c t i o n  N u m b e r
F i g u r e  2 S t e p  5 F i r s t  D E A E  - c e l l u l o s e  c o l u m n
D i a l y s e d  m a t e r i a l  (2 6  ml, 9 6 . 2  m g  p r o t e i n )  f r o m  ( N H ^ ) 2 S 0 ^
p r e c i p i t a t i o n  s te p  w a s  l o a d e d  on the c o l u m n  and e l u t e d  
w i t h  b u f f e r  A c o n t a i n i n g  100 m M - K C l .  F r a c t i o n s  (5ml) w e r e
c o l l e c t e d  a n d  a s s a y e d  for p r o t e i n s  (e ©) and h e x o k i n a s e
a c t i v i t y  (o— O) . T u b e s  25 - 32 i n c l u s i v e  w e r e  p o o l e d























0 . 0 5 70
F r a c t i o n  N u m b e r 400
F i g u r e  3 Step 6  S e c o n d  D E A E  - c e l l u l o s e  c o l u m n
D i a l y s e d  m a t e r i a l  (18 ml, 3 3 . 3  m g  p r o t e i n )  f r o m  s tep  5 was  
l o a d e d  on the c o l u m n  a nd  e l u t e d  w i t h  a l i n e a r  g r a d i e n t
0 - 120 mM K CI (----- ) in b u f f e r  A (20 0 m l) .  F r a c t i o n s
(5.5 ml) w e r e  c o l l e c t e d  a n d  a s s a y e d  for p r o t e i n  (#— o)
h e x o k i n a s e  a c t i v i t y  (0 - - 0 ) . 
p o o l e d .
and
T u b e s  2 5 - 4 0  i n c l u s i v e  w e r e
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Inhibition of brain hexokinase by glucose 6 -phosphate and its isosteric 
phosphonic analogue
Enzymic purity of 6,7, dideoxy-a-D-gluco-heptose 7-phosphonic 
acid (X) as measured by glucose 6 -phosphate dehydrogenase was found to 
be 75% compared to its value determined by weight. This is in agree­
ment with the result obtained for compound X prepared by Adams e_t a l . 
(1976) (P. Adams personal communication). Furthermore the value 
for compound X as a substrate for glucose 6 -phosphate dehydrogenase 
was in close agreement to that reported by Adams ^  (1976)
(Table 24).
Table 24. Comparison of for 6,7 dideoxy-a-D-gluco-heptose 
7-phosphonic acid
(yM) (pH 7.5)
Adams et al.(1976) 227±6
observed 232
The coupled-enzyme assay system used to measure hexokinase 
activity in the presence of product inhibitor was found to have a 
small initial rate which rapidly tailed off. This effect was 
observed in the assay medium containing only buffer, phosphoenol­
pyruvate, lactate dehydrogenase, pyruvate kinase, NADH, ATP and MgCl^.
As a result of a series of experiments in which one constituent at 
a time was omitted, the observed initial rate was attributed to the 
ATP sample and was assumed to result from the presence of a small 
percentage of contaminating ADP. Before addition of hexokinase to start 
the reaction, each assay was accordingly incubated for 15 min to allow 
enzymic conversion of ADP to ATP. A very small but constant endogenous
-113-
rate was also observed with the purified hexokinase in the absence of 
substrates. The purified enzyme showed no contaminating phospho­
diesterase activity and a glucose oxidase/peroxidase coupled assay 
indicated the absence of glucose. In view of this, substrate concen­
trations were used such that the initial rate of the reaction was at 
least 50 times greater than the endogenous rate. Prior to any kinetic 
experiments the purified hexokinase was dialysed overnight in buffer A 
minus glucose.
Bovine brain hexokinase (isoenzyme I) was prepared after the 
procedure of Redkar & Kenkare (1972) as described above and had a 
specific activity of 24 units/mg.
The mean and standard deviations of intial velocities through 
a wide range of glucose concentrations (Table 25) indicated that the 
standard deviations in initial velocity measurements are "simple"
(i.e. the standard deviation of initial velocity values is independent 
of glucose concentrations) as apposed to the situation where each - 
velocity has a standard deviation proportional to its true value (i.e. 
"relative") (Cornish Bowden, 1976; Henderson, 1978). All kinetic 
parameters determined in this section were calculated with a weighting 
procedure assuming "simple" errors in initial velocity measurements.
Figures 4A and 4B illustrate inhibition of glucose 6 -phosphate 
2-
relative to MgATP and glucose respectively and Figures 6 A and 6 B
illustrate inhibition of 6,7 dideoxy a-D-gluco-heptose 7-phosphonic
2-  ~  .
acid relative to MgATP and glucose respectively. Qualitatively
glucose 6 -phosphate and 6,7 dideoxy-a-D-gluco-heptose 7-phosphonic acid 
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both being competitive inhibitors of MgATP^ and non competitive 
inhibitors of glucose. Apparent dissociation constants 
and K^iHtercepts^ were obtained from the secondary plots of slopes 
and intercepts versus the relayant inhibitor (Table 26).
Quantatively 6,7 dideoxy-a-D-gluco-heptose 7-phosphonic acid 
appears to be a less potent inhibitor of brain hexokinase I compared 
to the natural product inhibitor glucose 6 -phosphate, with apparent 
values 50 to 100 fold larger for the phosphonate analogue. The 
values obtained for glucose 6 -phosphate were of the same order as those 
obtained by Grossbard & Schimke (1966) for rat brain hexokinase I 
[k^ 0.21mM and (MgATP^’ varied substrate) 0.026mM|.
True K. values cannot be derived directly from any primary or 
1
secondary kinetic plot of product inhibition where the reaction 
mechanism is rapid equilibrium random order [as shown for this enzyme; 
Ning e_t £ l . (1969), Bachelard e^ (1971) and Gerber ^  a d . (1974)]
The derived apparent and %^in^Grcept ^^lues are complex factors
including substrate kinetic constants in addition to true values. 
Therefore additional kinetic studies were performed on the purified 
brain hexokinase (Figures 8 A and BB) to determine the substrate kinetic 
constants necessary to calculate the true and values for glucose
6 -phosphate and 6,7 dideoxy-a-D-gluco-heptose 7-phosphonic acid 
[k.^ , dissociation constant of enzyme inhibitor complex (El); 
dissociation constant of inhibitor from enzyme-glucose-inhibitor complex 
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E - glucose - I
1 = glucose 6 -phosphate or analogue X
and values obtained (Table 28) show clearly that qualitatively 
inhibition by glucose 6 -phosphate and 6,7 dideoxy-a-D-gluco-heptose
7-phosphonic acid act in an identical manner with respect to bovine 
brain hexokinase I, but quantitatively the phosphonate analogue appears 
to be a much less potent "product" inhibitor, with and values 
8 8  and 63 times larger than the corresponding values for glucose 
6 -phosphate.
The value for glucose 6 -phosphate obtained by me differed
significantly from that obtained by Casazza & Fromm (1976)(35yM and lyM
ATP
respectively). This is possibly a consequence of larger and 
values (Table 27) obtained and used in the presently described work.
The and values for glucose 6 -phosphate and its analogue (X) were 
accordingly determined using the kinetic constants obtained for bovine 
brain hexokinase by Casazza & Fromm (1976) (also shown in Table 27).
The and values for glucose 6 -phosphate computed on this basis
-11%-
Table 27. Substrate kinetic constants obtained from secondary plots of 
slopes and intercepts from Figures 8 A  and 6 B (secondary plots,Figures 
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Assuming the model of glucose 6 -phosphate product inhibition as 
proposed by Casazza & Fromm (1976)(Scheme 5), the results obtained 
for glucose 6 -phosphate inhibition (Figures 4A and 4B) and 6,7 dideoxy- 
g-D-gluco-heptose 7-phosphonic acid inhibition (Figures 6 A and 6 B) were 
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are seen to be in much closer agreement with those obtained by 
Casazza & Fromm (1976)(Table 29).
Most importantly, 6,7 dideoxy a-D-gluco-heptose 7-phosphonic 
acids acts in an identical manner to glucose 6 -phosphate as a product 
inhibitor of bovine brain hexokinase I, but less potently (K^ and 
values being 50-80 times greater than for glucose 6 -phosphate) 
irrespective of the treatment of the results obtained.
Glucose 6 -phosphate has been shown not to inhibit brain hexo­
kinase to the same extent at pH 4.6 as at higher pH values (Crane & 
Sols, 1954) and it was suggested that the mono anionic glucose 6 - 
phosphate form is not an inhibitory species. As the second pK of the 
phosphonate analogue (X) (7.46) differs by only 1.25 units from that 
of the natural substrate (6.21) (Adams e_t a T ., 1976) no more than a 15- 
fold discrimination could be achieved at any pH by the preference for 
a particular ionic form (Dixon & Sparkes, 1974). It is accordingly 
unlikely that the ionic state of the analogue is a major factor in 
determining its higher values compared with those of glucose 6 - 
phosphate. The apparent decrease in affinity caused by replacing the 
C-O-P grouping of the natural substrate by C-CH^-P could result from 
specific interactions of the oxygen atoms or from minor geometric 
changes resulting from the substitution. The decreased inhibitory 
capacity of the phosphonate compared with that of the natural phosphate 
clearly reflects the high degree of specificity for the binding site 
for the phosphate moiety of glucose 6 -phosphate in product inhibition 
of hexokinase.
F i g u r e  4 L i n e w e a v e r - B u r k  p l o t s  fo r the i n h i b i t i o n
of h e x o k i n a s e  by g l u c o s e  6 - p h o s p h a t e .  R e a c t i o n  
c o n d i t i o n s  as d e s c r i b e d  in the M a t e r i a l s  and M e t h o d s .
(A) G l u c o s e  c o n c e n t r a t i o n  h e l d  c o n s t a n t  ( 0 . 5 m M ). 
C o n c e n t r a t i o n  of g l u c o s e  6 - p h o s p a t e ;  0 , 0  ; A , 0 . 0 2 8 m M ;
□ , 0 . 0 4  2mM; o , 0 . 0 8 4  m M .
2 -
(B) M g A T P  c o n c e n t r a t i o n  h e l d  c o n s t a n t  (2.0 m M ) . 
C o n c e n t r a t i o n  of g l u c o s e  6 - p h o s p h a t e ;  o , 0 ; A , 0 . 0 2 8 m M ;
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F i g u r e  5 S e c o n d a r y  p l o t s  of s l o p e s  and i n t e r c e p t s  (f rom  
F i g u r e  4 ) v e r s u s  g l u c o s e  6 - p h o s p h a t e  c o n c e n t r a t i o n .
F i g u r e  6 L i n e w e a v e r - B u r k p l o t s  f or the i n h i b i t i o n  of 
h e x o k i n a s e  by a n a l o g u e  X. Re action- c o n d i t i o n s  as 
d e s c r i b e d  in the M a t e r i a l s  a n d M e t h o d s ,
(A) G l u c o s e  c o n c e n t r a t i o n  h e l d  c o n s t a n t  ( 0 .5m M).  
C o n c e n t r a t i o n  of a n a l o g u e  X; o  , 0 Î ^ > 1 . 4 3 2 m M ;  □ ,
2 . 8 6 m M .  2 _
(B) M g A T P  c o n c e n t r a t i o n  h e l d  c o n s t a n t  (2. 0m M ),  
C o n c e n t r a t i o n  of a n a l o g u e  X; O , 0; a  , 0.692mM.
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F i g u r e  7 S e c o n d a r y  p l o t s  of s l o p e s  a nd i n t e r c e p t s ( f r o m  
f i g u r e  6 ) v e r s u s  a n a l o g u e  X c o n c e n t r a t i o n .
F i g u r e  8 L i n e w e a v e r - B u r k  . plots,
(A) 1/V v e r s u s  1/ |Mg A T P ^ ^  m M  w i t h  t h e  f o l l o w i n g
g l u c o s e  c o n c e n t r a t i o n s :  O , l.O m M ;  a  , 0 . 5 m M ;  □ ,
0 . 2 5mM; • , 0 . I m M ; A 0 . 0 5 m M .
(B) l^y v e r s u s  1/ [ g l u c o s ^  m M  w i t h  t h e  f o l l o w i n g  
M g A T P  c o n c e n t r a t i o n s ;  O , 2 . 0 m M ;  a  , l . O m M ;  □, 0 . 5 m M ;
•, 0.2 5mM;A , O . l m M .
Reaction c o n d i t i o n s  as d e s c r i b e d  in M a t e r i a l s  a n d  
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F i g u r e  9 S e c o n d a r y  P l o t s
(A) I n t e r c e p t s  f r o m  1 / V  v e r s u s  1 / ^ M g A T P ^ ^ m M  ( F i g u r e  8 A) 
v e r s u s  1/ [glucose] m M  .
(B) I n t e r c e p t s  f r o m „ l / V  v e r s u s  l / [ g l u c o s ^ m M  ( F i g u r e  8 B) 
v e r s u s  1 / [ M g A T P  JraM.
Ce) S l o p e s  f r o m  1 / V  v e r s u s  1/ ^ g A T P m M  ( F i g u r e  8 A) 
v e r s u s  1/ [ g l u c o s ^ m M .
(D) S l o p e s  f r o m  1 / V „ v e r s u s  1/ [ g l u c o s ^ m M  ( F i g u r e  8 B) 
v e r s u s  1 / [MgATP J m M .
Enzymic synthesis of 6,7 dideoxy-D-gluco-heptonic 
7-phosphonic acid, its purification and interaction 
with gluconate 6 -phosphate dehydrogenase
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INTRQDUCTION
Adams e_t ^  (1976) reported that analogue X mimics glucose
6 -phosphate in acting as a substrate for yeast glucose 6 -phosphate 
dehydrogenase (see page 62). Furthermore use of a coupled assay 
system suggested that the oxidation product of this enzymic 
dehydrogenation [presumed to be the isosteric phosphonate analogue 













yeast gluconate 6 -phosphate dehydrogenase. A similar result was 
obtained by Webster et al. (1976) who showed that the isosteric 
analogue of fructose-6 -phosphate is a substrate for the
sequential action of glucose 6 -phosphate isomerase, glucose 6 -phosphate 
dehydrogenase, and gluconate 6 -phosphate dehydrogenase. On the basis 
of their results both groups of workers pointed out the possibilities 
of enzymic conversion of the glucose 6 -phosphate analogue (X) into 
the corresponding analogue of ribose 5-phosphate and, even into 
analogues of nucleotides. Introduction of any of these analogues into 
a living cell by way of permeable derivatives could Jead to intra­
cellular release of the phospbonaro analogues which might be converted 
into nucleotide analogues capable of preferenrrally biting nucleic
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acid metabolism, e.g. for therapeutic purposes.
The work to be reported in this section concerns; (A) the 
enzjTnic synthesis of 6,7 dideoxy D-gluco-heptonic 7-phosphonic acid 
(CXXI) from the isosteric analogue of glucose 6 -phosphate (X) via 
a cyclic assay system. (B) The purification of compound CXXI by 
anion exchange columh chromatography. (C) A  comparison of the 
kinetics of the dehydrogenation (at pH 7.5 and pH 8.0) by yeast 
gluconate 6 -phosphate dehydrogenase of gluconate 6 -phosphate and of




Gluconate 6 -phosphate dehydrogenase (yeast)(EC 1.1.1.44.), 
glutamate dehydrogenase (beef liver)(EC 1.4.1.3.), gluconate 6 - 
ph.osphate, and a-keto glutarate were purchased from Boehringer Corp. 
(London) Ltd., W.,5. U.K. MN 300 cellulose powder, particle size 
< lOyM was obtained from Machery, Nagel and Co., Duren, Germany.
Sepliadex A-25, anion-exchange beads, particle size 40-120ym, were 
purchased from Pharmacia (Great Britain), Hounslow, Middlesex, U.K. 
Reagents used in work described earlier in this thesis were obtained 
from sources previously quoted and all other chemicals were purchased 
from BDH Chemicals, Pool, Dorset, U.K.
Glucose 6 -phosphate, 6,7 dideoxy a-D-gluco-heptose 7-phos­
phonic acid and NADP were determined as described earlier (page 102). 
Gluconate 6 -phosphate and 6,7 dideoxy g-D-gluco-heptonic 7-phosphonic 
acid were determined as described for glucose 6 -phosphate except 
gluconate 6 -phosphate dehydrogenase (0.48 I.U) replaced glucose - 
6 phosphate dehydrogenase.
Kinetic determinations
Initial rates of gluconate 6 -phosphate dehydrogenase reactions 
were followed by determining the formation of NADPH from NADP^. The 
increase in E^^^ was measured in a Unicam 8-100 spectrophotometer at 
25^0. Reaction mixtures contained varying concentrations of substrates 
in lOOmH-Tris-base buffer adjusted to the required pH with 2M-HC1 in 
a 4cm-pathlength cell (total volume 4.005ml). Reactions were 
initiated by the addition of enzyme [j-Pg (for glucose 6 -phosphate) or 
5yg (for analogue CXXI)i in buffer 5yl) containing 1% bovine serum
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albumin. A standard assay for gluconate 6 -phosphatc dehydrogenase
activity using 0,45raM-NADP'*' and 1. 2inM-gluconate 6 -phosphate, was
performed at regular intervals during each experiment to check the
stability of the enzyme. Initial rates were determined for five
concentrations of one substrate at each of five different fixed
concentrations of the alternate substrate. Values of K and V
m max
were obtained by extrapolation to infinite concentration of alternate 
substrate as described by Florini & Vestling (1957), by using slopes 
from [s_j/Vo versus [s] plots which were calculated by weighted regression 
(assuming simple error) using a computer programme based on the 
procedure described by Cornish-Bowden (1976).
Phosphate or phosphonate determination
(i) Ashing of phosphate (or phosphonate) sample with Mg (NO^)^
This procedure follows that described by Ames & Dubin (1960). 
The phosphate (or phosphonate) sample (10yl-200yl) was mixed with 10% 
Mg(N0 ^)2 . ^H^O (w/v) in 95% ethanol in a pyrex test tube. The 
mixture was evaporated to dryness over a strong bunsen flame with rapid 
shaking and further heated in the flame until the brown fumes had 
disappeared. O.IM HCl (0.3ml) was added to the cooled tube which was 
capped with silver foil and heated in a boiling water bath for 15 min.
(ii) Phosphate assay
Inorganic phosphate was then determined using the sensitive 
procedure described by Chen elt a_l. (1956). The phosphate sample was 
diluted (to 4m) with doubly-distilled water, reagent C (4ml) was added 
and the tube was capped with parafilm. The contents of the tube were 
mixed, incubated for 2 hr. at 37^C and then cooled to room température 
when the absorbance was read (Unicam SP 8-100, or SP 500 spectre-
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photometer) at 820nrm (1‘Ocm path-length cell) against a blank solution. 
K^HPO^ was used to obtain standard curves which were linear in the 
range 1-0.35 ymoles phosphorus (see Figure 10). Solution C. was made 
up daily and stored on ice. It contained 6 M-sulphuric acid (1 vol.), 
2.5mM-ammonium molybdate (1 vol.), 10% ascorbic acid (stable for one 
month at 0°C) (1 vol.) and doubly-distilled water (2 vol.). All glass­
ware used was cleaned in chromic acid and rinsed twice with distilled 
and once with doubly-distilled water.
Thin layer chromatography
Following the procedure of Waring & Ziporin (1964) , cellulose 
MN300 t.l.c. plates were spotted with aliquots of glucose 6 -phosphate 
and gluconate 6 -phosphate and developed in either solvent A  [water - 
poor phase from a mixture of t-amyl alcohol (60ml), doubly-distilled 
water (30ml) and p^-toluenesulphonic acid acid (2g)[] or solvent B 
Fisobutyric acid (6 6 ml), concentrated ammonium hydroxide ( 1  ml) and 
doubly-distilled water (33ml)^ . 6 - 8  hr were required for the solvent
front of solvent A to move 18cm, and 3-4 hr for the solvent front of 
solvent B to move 14-16cm. Detection of the sugar phosphates was 
accomplished with spray reagent A [[ 10% SnCl^ H^O in HCl (concentrated 
HCl freshly-distilled 200 fold with 0 .5 M-H 2 S0 ^)J or spra^ B [cysteine 
hydrochloride (0.75g), 50% ethanol (2 0 ml) and concentrated H^SO^ (5ml)J . 
After spraying, the plates were heated for 5 min at 100°C. Commercially- 
prepared silica gel G plates were also used.
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EXPERIMENTAL, RESULTS, AND DISCUSSION
The chemical oxidation of 6,7 dideoxy-a-D-gluco-heptose 
7-phosphonic acid (X) by bromine was known to present difficulties 
(P. Adams, personal communication) and so an enzymic preparation of 
the analogue CXXI was sought. Scheme 6 illustrates the reaction 
sequence that was devised in order to minimise levels of NADPH which 
is known to act as a product inhibitor of glucose 6 -phosphate dehydro­
genase (Afolayan 1972).






















Preparative and separation methods were established using glucose
6 -phosphate as substrate in order to conserve the phosphonate 
analogue during experimental stages.
Enzymic synthesis of gluconate 6 -phosphate or 6 ,7-dideoxy-P-gluco- 
heptonic 7-phosphonic acid (CXXI)
Preparation
The cycling procedure used was based on that described by 
Lowry et al. (1961). The reaction mixture contained 5mM- a keto­
glutarate, 3mM-glucose 6 -phosphate (or 6,7 dideoxy a-D-gluco-heptose
7-phosphonic acid), 25mM-ammonium acetate, 0.2mM-ADP, 2mM-NADP , bovine 
serum albumin (2mg/ml), glutamate dehydrogenase (80yg/ml) and glucose 
6 -phosphate dehydrogenase (6 yg/ml) in 50mM-Tris—base buffer adjusted
to pH 8.0 with 2M-HC1 (total volume, 50ml). The cyclic reaction was 
initiated by the addition of NADP^ and the mixture was incubated for 
16 hr at room temperature. The reaction was terminated by heating the 
mixture at 100°C (boiling water bath) for 2-6 min, and the resulting 
mixture was allowed to cool to room temperature over a period of 3 hr 
when a precipitate of deactivated enzymes appeared. Charcoal (lOOmg) 
was added and the mixture was allowed to stand overnight at 4°C.
The charcoal, denatured proteins and nucleotides were removed by 
filtration and washed with doubly-distilled water (63 m l ) . Filtrate • 
and washings were combined. Samples (1ml) of the reaction mixture 
were monitored at 340nm and showed an initial slight increase in E^^Q 
followed by a drop to a steady level somewhat below that of the 
starting value. It is possible that these changes could result from 
contamination of NADP by NADPH which was initially oxidised. Such an 
explanation would lead to a value of approximately 13% contamination
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of NADP"^ by NADPH.
a Ketoglutarate concentration was found to be optimal at 5mM, 
as lower levels led to decreased overall rates of product formation, 
whereas higher levels apparently inhibited the dehydrogenation of 
glucose 6 -phosphate or its analogue. Ammonium ion concentrations up 
to lOOmM were found not to affect the reaction and both enzymes were 
accordingly added together with their ammonium sulphate-containing 
stock solutions. The system described above was found to be suitable 
for glucose 6 -phosphate or analogue concentrations of up to 5mM.
ADP was present in order to stabilize glutamate dehydrogenase.
Separation of glucose 6 -phosphate from gluconate 6 -phosphate
Separation of commercial glucose 6 -phosphate from commercial 
gluconate 6 -phosphate was initially investigated using the thin layer 
chromatographic system described by Waring & Ziporin (1964) (Materials 
and Methods) which was found not to be satisfactory.
The separation of glucose 6 -phosphate and gluconate 6 -phosphate 
from the components of the cyclic reaction mixture was examined using 
Amberlite CG 400 anion - exchange resin in a procedure based on that 
of Lefebvre e_t a l . (1964) , Amberlite CG 400 anion exchange (Cl form) 
was converted into the borate form by washing with 0.8M potassium 
tetraborate ( 2 0  bed volumes) until all the chloride ions had been dis­
placed. It was then washed with doubly-distilled water until the 
eluent gave no precipitate on addition of silver nitrate. The resin 
was equilibrated by passing 0.IM-ammonium tetraborate (20 bed volumes) 
through the column. The completed reaction mixture (containing 
approximately ImM gluconate 6 -phosphatc) was adjusted to pH 8.0 with
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amraonium hydroxide, applied to the column, and eluted with a linear 
gradient of ammonium tetraborate (0.1-0.4M, 800ml) at a flow rate of 
1.4ml/min at room temperature. Fractions (10ml) were collected and 
aliquots of every third fraction were taken for phosphate deter­
mination. Phosphate-containing fractions were pooled and freeze- 
dried to give a white powder to which methanol was added and removed 
by evaporation in attempts to obtain sugar phosphates freed from 
salts.
A good separation of glucose 6 -phosphate and gluconate 6 - 
phosphate from each other and from components of the reaction mixture 
was obtained by this method (Figure llA). However, all attempts to 
free the sugar phosphates from borate salts were unsuccessful and the 
procedure was abandoned.
A  more useful separation of glucose 6 -phosphate and its 
oxidised product was achieved by use of a DEAE-Sephadex A-25 column 
and elution with potassium bicarbonate based on a method described 
by Loesche e_t (1974).
DEAE-Sephadex A-25 (Cl form)(20g) was allowed to stand in 
1M-KH30^ for several days and then in 50mM-KHC0^ for 48 hr before 
packing into a column (30cm x 1.7cm) which was equilibrated by elution 
with bOmM-KHCO^ (1500ml). A mixture of commercial glucose 6 -phosphate 
(6 6 ymoles) and gluconate 6 -phosphate (58 ymoles) in 50mîl KHCO^ ( 1 0  ml) 
was applied to the column and eluted with a linear gradient (50mM- 
400mM, 400ml) at a flow rate of l.Oml/min. Fractions (7.5ml) were 
collected and aliquots of every third fraction were taken for phosphate 
determination (Figure 12A). Phosphate-rich fractions were enzymically-
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assayed by using glucose 6 -phosphate dehydrogenase and gluconate 
6 -phosphate dehydrogenase. Fractions showing the latter activity 
were combined and stirred with Dowex 50 W-Xl (H form, 50-100 mesh) 
cation-exchange beads until bubbling ceased. This procedure was 
performed under vacuum to facilitate the escape of CO^ and thus to 
minimize any consequent acidification. The Dowex resin was removed 
by filtration and the filtrate was shell-frozen and freeze dried to 
give a pure sample of -the free sugar phosphate acid.
In view of the successful separation of commercial phosphates 
(Figure 12A), the method was applied to purification of the reaction 
mixture used to convert glucose 6 -phosphate into gluconate 6 -phosphate. 
The completed reaction mixture (generated from approximately 300ymol 
glucose 6 -phosphate) was adjusted to pH 8.4 with 2M-Tris-base, applied 
to a Sephadex column and eluted as described above (Figure 12B, 
typical separation achieved). Gluconate 6 -phosphate was so obtained 
in a suitable state of purity and in 57% overall yield (by enzymic 
assay). Phosphate and enzymic determinations at various stages of the 
preparation are shown in Table 30.







Glucose 6 -phosphate added to cyclic 
mixture
184.7 184.6
Gluconate 6 -phosphate, inactivated 
filtered cycling mixture
250.0 145.0
Gluconate 6 -phosphate, peak from 
Sephadex anion exchange column
1 2 2 . 0 111.4




Separation of 6 ,7-dideoxy-D-gluco-heptonic 7-phosphonic acid (CXXI) 
from its precursor 6,7 dideoxy a D-gluco-heptose 7-phosphonic acid (X)
The chemically-prepared sample of analogue X used as 
substrate in the enzymic synthesis of CXXI was purified on Sephadex 
A-25 prior to the reaction. A  single major peak of "phosphate” was 
eluted at 330mM-KHC0^ (Figure 13A) and was shown by enzymic assay to 
represent 93% recovery of starting material (Table 31).
Table 3 1 . Elution and recovery of analogue X from Sephadex A-25 







analogue X added to column 179 164
analogue X, peak from Sephadex 
anion exchange column
134 159
analogue X free acid, after 
cation exchange
134 151
The purified phosphonate (X) was dehydrogenated by means of the 
cyclic reaction system and the completed reaction mixture was separated 
on Sephadex A-25 (Figure 13B) as described for gluconate 6 -phosphate 
prepared as above. The overall yield of analogue CXXI, by enzyme assay 
was 56% (Table 32).
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analogue X added to cycling mixture 245 289
analogue CXXI inactivated filtered 
cycling mixture
288 181
analogue CXXI, peak from Sephadex 
anion exchange column
172 161.3
analogue CXXI, free acid from 
cation exchange
173 161
The high values obtained by phosphate determination for the 
inactivated cyclic mixtures clearly reflect the presence of phosphate- 
containing constituents of the cyclic mixture as well as gluconate 
6 -phosphate or its phosphonate analogue (Table 30 and Table 32 
respectively). A.comparison of the yields at various stages in the 
purification of gluconate 6 -phosphate and of its phosphonate analogue 
(GXXI) as determined by enzymic assay is shown in Table 33.
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Table 33. Comparison of yields for the synthesis and purification of 
gluconate 6 -phosphate and its phosphonate analogue (CXXI)
Yield for invididual step %
Fraction gluconate 6 -phosphate analogue CXXI
enzymic synthesis 79 70
separation from other inactivated 
cyclic mixture constituents by 
Sephadex anion exchange
79 89
free acid form, after cation exchange 77 99
overall yield 57 56
Comparison of activities of gluconate 6 -phosphate and its analogue CXXI 
as substrate for gluconate 6 -phosphate dehydrogenase
In order to check that the kinetic parameters of enzymically- 
synthesised gluconate 6 -phosphate (and by implication those of its 
phosphonate analogue) were not affected by any impurities not detected 
by phosphate assay, the parameters were compared with those of the 
commercial compound and with literature values. The kinetic parameters, 
at pH 7.5, for enzymically-synthesised gluconate 6 -phosphate and 
commercial 6 -phosphate (trisodium salt) were found to be in reasonable 
agreement with each other (Table 34, Figures 14-17) and with those 
published by Pontremoli et al, (1961).
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Table 3 4 . Comparison of kinetic parameters of commercial gluconate- 
6 -phosphate, enzyraically synthesised gluconate 6 -phosphate 
and literature values of commercial gluconate 6 -phosphate as 















119 ± 6 4.3 ± 0.5 1
synthetic gluconate 
6 -phosphate
156 ± 12 4.3 ± 1.4 1
commercial gluconate 
6 -phosphate
(reported by Pontremoli 
et a l ., 1961)
160 25
Values are ± SE,
These latter authors found that the Michealis constants for gluconate 
6 -phosphate and NADP* of the concentration of the fixed substrate, and 
concluded that their data fitted a random order mechanism (where all 
the equilibria are adjusted rapidly except for the rate-determining 
step, consisting of the breakdown of a single ternary complex). It 
was, therefore, assumed that the enzymically-synthesised and purified 
gluconate 6 -phosphate, was essentially pure, containing no contaminants, 
that would significantly alter its kinetic parameters for yeast 
gluconate 6 -phosphate dehydrogenase. A similar case is accordingly 
argued for its phosphonate analogue (CXXI).
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Analogue CXXI was dehydrogenated by NADP^ in the presence of
gluconate 6 -phosphate dehydrogenase showing Michaelis-Menton kinetics
(Figures 20-23). The kinetic parameters for this reaction are
compared with those for the natural substrate, gluconate 6 -phosphate
NADP • ’
(commercial) in Table 35. The similarity of values for
gluconate 6 -phosphate and its phosphonate analogue (CXXI) suggests 
that the mechanisms of the enzymic reactions do not differ greatly 
in the two cases. If is regarded as a crude measure of affinity 
of the substrate for the enzyme then it is apparent that at both pH 
values examined, the binding of the analogue CXXI is significantly 
weaker than that of gluconate 6 -phosphate. The Introduction section 
of this thesis contains a number of examples in which replacement of 
a naturally-occurring phosphate by its phosphonate analogue led to a 
reduced enzyme-substrate interaction as shown by standard kinetic 
parameters. A number of rationalizations were offered in these cases 
and such explanations can be examined,here also. The second pKa 
values of phosphonates are generally found to exceed those of their 
corresponding phosphates by approximately 1.0 pKa unit (Freedman &
Doak, 1957; Engel, 1977) and different kinetic parameters can sometimes 
be attributed to different states of ionisation of a naturally substrate 
and its analogue under the conditions of the assay. At pH 7.5 the 
value for analogue CXXI is over three times higher than that of 
gluconate 6 -phosphate which might be thought to reflect, at least 
partially, the lower degree of ionization of the analogue at this pH 
(assuming pKa values of 6 and 7 respectively, gluconate 6 -phosphate 
and its analogue would contain approximately 97% and 76% of the 
trianionic forms at pH 7.5). In this case raising the pH of the assay











































































analogue CXXI (corresponding to an increase in trianionic form from 
76% to 90%) while changing that of gluconate 6 -phosphate very little 
(trianionic form increases from 97% to 99%). If in fact the ionisation 
of substrate does effect the kinetic parameters in this way the effect 
is masked by a general two fold increase of of both substrates 
attributable to other factors (Table 35). At pH 8.0 the of 
analogue CXXI is still some three fold greater than that of gluconate 
6 -phosphate and the conclusion must be that these differences are not 
mainly caused by the relatively small differences in content of 
trianionic form (90% versus 99%) at this pH, The situation is far 
from clear, however as the pH profile of initial reaction rates 
(Figure 24) would be consistent with an increasing rate of dehydrogenation 
of both substrates as their contents of trianionic form increased to 
approximately 90% followed by decreasing rates as the pH increases 
further.
The apparent decrease in affinity caused by replacing the 
C-O-P grouping of the natural substrate by C-CH^-P could result either 
from specific interactions of the oxygen atoms or from minor geo­
metric changes resulting from the substitution. These changes are 
reflected in the markedly lower values of the analogue compared
with those of gluconate 6 -phosphate (Table 35).
Enzymic synthesis of ribulose 5-phosphate
A preliminary investigation of the conversion of glucose 
6 -phosphate, by two enzymic cycling steps and one anion exchange 
column, to demonstrate the formation of ribulose 5-phosphate was 
carried out (Figure IIB). The inactivated constituents of a first 
cycling mixture (containing no glucose 6 -phosphate but only gluconate
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6 -phosphate by enzjmic assay) were not separated by anion-exchange 
chromatography but were subjected to a second cyclisation procedure 
under the same conditions as the first (page 133) except that 
gluconate 6 -phosphate dehydrogenase was added in place of glucose 
6 -phosphate dehydrogenase. The inactivated constituents of the 
second cyclisation mixture displayed neither glucose 6 -phosphate 
dehydrogenase nor gluconate 6 -phosphate dehydrogenase activity and 
were passed down on anion exchange column (Figure IIB). The major 
phosphate peak was eluted in a position which might be expected to 
correspond to that of ribulose 6 -phosphate (around 200mM ammonium 
tetraborate). This result suggests the possibility of the enzymic 
conversion of the glucose 6 -phosphate analogue (X) into the phosphonate 
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F i g ure 11
F i g u r e  12 E l u t i o n  of p h o s p h a t e - c o n t a i n i n g  f r a c t i o n s  
f r o m  S e p h a d e x  A - 2 5  a n i o n  e x c h a n g e  c o l u m n .
(A) S e p a r a t i o n  of c o m m e r c i a l  g l u c o s e  6 - p h o s p h a t e  a n d  
g l u c o n a t e  6 - p h o s p h a t e  u s i n g  a l i n e a r  g r a d i e n t  of 
K H C O ^  ( 5 0 m M - 4 0 0 m M ,  4 0 0 m l ) .  C o l u m n  d i m e n s i o n s  l*7cm x 
30cm. f l o w  r a t e  I m l / m i n .
( B ) S e p a r a t i o n  of e n z y m i c a l l y  p r e p a r e d  g l u c o n a t e
6 - p h o s p h a t e  f r o m  o t h e r  c y c l i c  r e a c t i o n  c o n s t i t u e n t s  
u s i n g  a l i n e a r  g r a d i e n t  of K H C O ^  ( 5 0 m M - 4 0 0 m M ,  5 0 0 m l ) .  
G l u c o s e  6 - p h o s p h a t e  C25|imoles) w a s  a d d e d  to c y c l i c  
m i x t u r e  p r i o r  to e l u t i o n  to act as a m a r k e r  in the 
e l u t i o n  p r o f i l e .  C o l u m n  d i m e n s i o n s  1 . 7 c m  x 35 cm, 
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F i g u r e  12
F i g u r e  13 E l u t i o n  of p h o s p h a t e - c o n t a i n i n g  
f r a c t i o n s  f r o m  S e p a d e x  A - 2 5  a n i o n  e x c h a n g e  c o l u m n .
(A) P u r i f i c a t i o n  of a n a l o g u e  X, u s i n g  a l i n e a r  
g r a d i e n t  of K H C O ^  ( 5 0 m - 4 0 0 m M ,  3 0 0 m l ) .  C o l u m n  
d i m e n s i o n s  1 . 4 c m  x 20cm, f l o w  r a t e  1 . 4 m l / m i n .
CB) S e p a r a t i o n  of 6,7, d i d e o x y  D - g l u c o  - h e p t o n i c
7 - p h o s p h o n i c  a c i d  (CXXI) p r o d u c e d  e n z y m i c a l l y  f r o m
6,7 dideoxy.-a-D g l u c o - h e p t o  se 7 - p h o s p h o n i c  a c i d  (X), 
u s i n g  a l i n e a r  g r a d i e n t  of K H C O ^  ( 5 0 m M - 4 0 0 m M ,  5 0 0 m l )  
C o l u m n  d i m e n s i o n s  1.7 c m  x 35cm, f l o w  r a t e  1 . 4 m l / m i n .  
Th e  f i r s t  p e a k  e l u t e d  s h o w e d  no g l u c o s e  6 - p h o s p h a t e  
































































F r a c t i o n  n u m b e r 80
F i g u r e  13
F i g u r é  14 L i n e w e a v e r - B u r k  p l o t s .  A ll  a s s a y s  
w e r e  c a r r i e d  out at pH 7.5.
CA) 1/V v e r s u s  1/ [gluconate 6 - p h o s p h a t e ]  m M  
w i t h  th e f o l l o w i n g  N A D P  c o n c e n t r a t i o n s ;
O j 0 . 4 4 8 m M ;  a  , 0 . 1 3 5 m M ;□ 0 . 0 4 5 m M ; # , 0 . 0 0 8 9 m M .
CB) 1/V v e r s u s  1/ ^ A D P  J m M  w i t h  th e f o l l o w i n g  
g l u c o n a t e  6 - p h o s p h a t e  c o n c e n t r a t i o n s ;  o , 0 . 6 5 7 m M ;
A , 0 . 2 1 9 m M ; □ , 0 . 1 6 4 m M ; ® , 0 . 0 9  8 5 m M ; a , 0 . 04  9 m M . 
G l u c o n a t e  6 - p h o s p h a t e  wa s e n z y m i c a l l y  s y n t h e s i s e d  

































1 / [ g l u c on a t e  6 - p h o s p h a t ^  m M
0  2 0
1 / g l u c o n a t e  6 - p h o s p h a t e  
m M
(A) I n t e r c e p t s  f r o m  1 /V  v e r s u s  \ !  fgluconate 6 - p h o s p h a t e j
( F i g u r e  14A) v e r s u s  1/ [n A D P  J  .
(B) I n t e r c e p t s  f r o m  1 / V  v e r s u s  1/ |n A D P ^  ( F i g u r e  14B)
v e r s u s  1 / g l u c o n a t e  6 - p h o s p h a t e j
(C) S l o p e s  f r o m  1 / V v e r s u s  1/ lu c o n  ate 6 - p h o s p h a t ë ]  
( F i g u r e  14A) v e r s u s  1/ (nADP^J
(D) S l o p e s  f r o m  1/V v e r s u s  1 / [nADP^[] ( Fi g u r e  14B) 
v e r s u s  1 / [ g l u c o n a t e  6 - p h o s p h a t e j .
Figure 16 Lineweaver-Burk plots. All assays 
were carried out at pH7.5.
(A) 1/V versus 1/ (gluconate 6 -phosphate) mM with
the following NADP+ CONCENTRATIONS: 0.883 mM;
A, 0.353 mM; □ , 0.087 mM; O  , 0.022 mM; A  , 0.009 mM.
(B) 1/V versus 1/(NADP'^) iriM with the following gluconate
6 -phosphate concentrations; 0.526 m M ; A , 0.263 mM; 
□  , 0.131 mM; 0 ,  0.079 mM; A  , 0.04 mM.




1/ [gluconate 6 - p h o s p h a t ^  m M0 25
50
1 /V
1/ [n ADP*^ m M 120


























^ 1 / [gluconate 6 - ph os ph a^ë j
F i g u r e  17
(A)
S e c o n d a r y  p l o t s
I n t e r c e p t s  f r o m  1 / V  v e r s u s  ^ / f g l u c o n a t e  6 -p hos ph âte l 
( F i g u r e  16A) v e r s u s  1 / [NADP j
(B) I n t e r c e p t s  f r o m  1 /V  v e r s u s  1/ [ n A D P ^  ( F i g u r e  16B) v e r s u s  
1 / [ g l u c o n a t e  6 - p h o s p h a t e j
(C) S l o p e s  f r o m  1 /V  v e r s u s  1/ [ g l u c o n a t e  6 - p h o s p h a t e ]  
( F i g u r e  16A) v e r s u s  l / [ N A D P ‘j
(D) S l o p e s  f r o m  1 /V  v e r s u s  1/ [ n A D P ^  ( F i g u r e  166) v e r s u s  
1 / [ g l u c o n a t e  6 - p h o s p h a t ë j  .
pigure 18 Lineweaver-Burk plots. All assays
were carried out at pH 8.0.
(A) 1/V l/(gluconate 6 -phosphate) mM with the
following NADP+ concentrations; 0.446 mM; A  , 
0.149 mM; □,0.045 mM; @  , 0.023 mM; ▲  ,
0.009 mM.
(B) 1/V versus 1/(NADP^) mM with the following
gluconate 6 -phosphate concentrations;
0.58 mM; A  , 0.29 mM; □  , 0.144 mM; ©  ,
0.087 mM; A  , 0.058 mM.









1 2 0 .







1/ [ g l u co na t e 6 - p h o s p h a t ^  m M
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1 / [gluconate 6 -phosphate[]
m M
F i g u r e  19 
(A)
S e c o n d a r y  p l o t s .
I n t e r c e p t s  f r o m  1 / V  v e r s u s  ^ / [ g l u c o n a t e  6 - ph o  spha te[] m M  
(F i g u r e  ISA) v e r s u s  1/ [NADP J
(B) I n t e r c e p t s  f r o m  1 /V v e r s u s  1/ [NADP j m M  C F i g u r e  18B) v e r s u s  
1 / [ g l u c o n a t e  6 -p ho sphate] m M  . •
(C) S l o p e s  f r o m  1/V v e r s u s  1/ [ g luc on at e 6 - p h o s p h a t e ] m M  
( F i g ur e  18A) v e r s u s  1/ [NADP J
(D) S l o p e s  f r o m  1/V v e r s u s  1/ [nADP^] ( F i g u r e  18B) v e r s u s  
1 / Jgluconate 6 - p h o s p h a t e ]  .
F i g u r e  20 L i n e w e a v e r - B u r k  p l o t s .  A i l a s s a y s  w e r e
c a r r i e d  out at p R  7-5
CA) 1 /V  v e r s u ^  1/ [ a n a l o g u e  CXXÏ] m M  w i t h  the 
f o l l o w i n g  N A D P  c o n c e n t r a t i o n s ;  O , 0 . 3 4 7  mM;
A, 0 . 1 0 5  m M ; □ , 0 . 0 3  5mM; • , 0 . 0 1 7  m M ; a  ,
0 . 0 0 7  m M ,
(B) 1 / V  v e r s u s  1 / j jîADP^JmM  w i t h  t h e  f o l l o w i n g
a n a l o g u e  C XXI  c o n c e n t r a t i o n s ;  O , 1 . 0 6  m M ; a  ,
































1 / [analogue CXXl] m M
F i g u r e  21 S e c o n d a r y  p l o t s .
(A) I n t e r c e p t s  f r o m  1 / V  v e r s u s  1/ [analogue CXXl] m M  
(F i g u r e  20A) v e r s u s  1/ [NADP j m M .
(B) I n t e r c e p t s  f r o m  1/V v e r s u s  1/ [nADP J m M  ( F i g u r e  20B) 
v e r s u s  1/ [ g lu c o n a t e  6 -phosphate[] mM,
(C) S l o p e s  f r o m  1 /y v e r s u s  1/ [analogue CXXl] m M  ( F i g u r e  20A.) 
v e r s u s  1/ [NADP J m M .
(D) S l o p e s  f r o m  1/V v e r s u s  1/ [nADP J  liiM ( F i g u r e  2ÔB) v e r s u s  










F i g u r e  22 L i n e w e a v e r - B u r k  p l o t s .  All a s s a y s  w e r e  
c a r r i e d  ou t at pH  8.0. ^A) 1/V v e r s u s  1/ [analogue C X X ^
m M , w i t h  f o l l o w i n g  N A D P  c o n c e n t r a t i o n s ;  o , 0 . 4 2 6 m M ;
A , 0 . 14 2mM; □ , 0 .04 3mM; © , 0 .0 2lmM; a , 0 . 00 9mM.
(B) 1/V  v e r s u s  1/ [NADP^mM w i t h  th e f o l l o w i n g  a n a l o g u e  
CXXl c o n c e n t r a t i o n s ;  O , 0 . 9 5 6 m M ;  a  , 0 . 6 3 7 m M ;  □ , 































0  1 / [analogue CXXl] m M  8
F i g u r e  23 
CA)
S c o n d a r y  p l o t s
I n t e r c e p t s  f r o m  1 /V  v e r s u s  1/ [ a n a lo g ue  CXXÏ] m M  
( F i g u r e  22A) v e r s u s  1 / [ n A D P  J m M ,  ^
(B) I n t e r c e p t s  f r o m  1 / V  v e r s u s  1/ [ N A D P ^ J m M  ( F i g u r e  22B)
v e r s u s  1/ [ a n al o gu e C X X l J m M .
(C) S l o p e s  f r o m  1/V v e r s u s  1/ [analogue CXXl] m M  ( Fi g u r e
22A) v e r s u s  1 / [ n A D P  J n M .  p -,
(D) S l o p e s  f r o m  1/ V  v e r s u s  1/ N A D P *  m M  ( F i g u r e  22B)
v e r s u s  1/ [analogue (XXI)^mM.
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0 . 0 1 5
Ini t ial 
R a t e
7.5 8,07.0 8.5
p H
F i g u r e  2 4 o f 
(©-
____________  E f f e c t  of pH  on the i n i t i a l  r a t e
d e h y d r o g e n a t i o n  of 7 7 y M  g l u c o n a t e  6 - p h o s p h a t e
a n d  2 18 pM analogue CXXl (O-^  O) . All assays contained
136 jjM NADP . The initial rates are expressed as the change 
in absorbance/min/25yg gluconate 6 -phosphate dehydrogenase.
- O )  ,
Effect of 6,7 dideoxy-g-P-gluco-heptose 7-phosphonic acid on cell 
proliferation of mouse lymphoma cells (LS 1210)
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INTRODUCTION
The Introduction section of this thesis contained a number 
of examples in which phosphonate analogues were shown to be capable of 
inhibiting mutant strains of E. coli and B. subtilus (pages 68-70.) 
Through the efforts of Engel and his co-workers (Kabak al^., 1972;
Shopsis e_t , 1972, 1973) it was shown that the isosteric phosphonate 
analogue (XCIII) of glycerol 3-phosphate was capable of inhibiting the 
growth of mutant strains of E. coli at low concentrations. The use of 
the tritiated form of analogue XCIII showed that such inhibition 
resulted from perturbation of normal phospholipid production. In 
treated E. coli there was a rapid inhibition of the rate of phosphatidyl- 
glycerol synthesis, a slower but almost as pronounced inhibition of the 
rate of phosphatidylethanolamine synthesis (Shopsis e^ , 1974) and
the appearance of a new phosphoglyceride, the phosphonate analogue 
(XCVI) of phosphatidyl glycerophosphate (Tyhach et a l ., 1976).
Analogue XCVI was a substrate and inhibitor of CDP diglyceride: sn- 
glycerol-3 phosphate phosphatidyltransferase (Cheng et al., 1975).
More recently Leifer e_t (1977) have demonstrated that analogue XCIII 
is actively transported into mutant strains of E. coli.
The isosteric phosphonate analogue (XCVII) of dihydroxyacetone- 
phosphate has been shown (Klein e_t al^., 1977) to be incorporated into 
the cell wall of B. subtilus, acting either as a bacteriocidal or 
bacteriostatic agent depending on the strain investigated. Goldstein 
et a l . (1974) demonstrated that the phosphonate analogue (XCIX) of 
glyceraldehyde 3-phosphate totally inhibited the growth of a mutant 
strain of E. coli. Most recently Tang e£ al^ . (1978) reported that the 
isosteric analogue (XCIV) of fructose 1-phosphate was an inhibitor 
of growth of mutant strains of E. coli capable of transporting phos­
— 161 —
phates. On the other hand the nonisosteric and isosteric phosphonate 
analogues (C and CII respectively) of glycerate 3 phosphate had no 
observable effect on several strains of Gram positive and Gram 
negative bacteria (Pfieffer et al., 1974).
In view of the above results a preliminary investigation 
of the effects of analogue X on the cell proliferation of mouse 
lymphoma cells (LS1210) was attempted.
“162-
METHODS AND MATERIALS 
Chemicals
Dulbecco’s modification of Eagles medium, feotal calf serum, 
glutamine, trypan blue and pencillin streptomycin were obtained from 
Flow Laboratories Ltd., Irvine, Ayrshire, U.K. Reagents used in work 
described earlier in this thesis were obtained from sources previously 
quoted and all other chemicals were purchased from BDH Chemicals, Poole, 
Dorset, U.K.
Mouse lymphoma cells (LS1210) were the generous gift of 
Dr. W.J.D. Whish. The cells were cultured in Medium A; (Dulbecco’s 
modification of Eagles medium supplemented with 10% feotal calf serum, 
2mM-glutamine and 100 units/ml pencillin, streptomycin) and grown at 
37°C under 5% CO^ in air. Asceptic technique was used throughout the 
procedure.
Typical procedure;- A stock solution of cells, approximately 1-2 x 10^
cells/ml, in stationary phase of growth were diluted 1 0  fold
(10ml -> 100ml, in medium A) and transferred to bijou bottles (9ml).
Cell proliferation was monitored by counting cell number on an 
improved Neubauer haemocytometer (average of eight counts). When 
cells entered the exponential phase of growth, lOmM-glucose 6 -phosphate 
or lOmM-analogue X or 150mM saline (1ml) (all solutions were made up 
in 5mM-Tribase buffer adjusted to pH 7.5 with 2M-HC1, and autoclaved 
for 5 min at 10 psi, prior to addition) was added to each bijou bottle 
(in duplicate) and cell proliferation regularly monitored.
Glucose 6 -phosphate and analogue X were determined as 
described earlier (page 1 0 2  ) •
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RESULTS AND DISCUSSION 
Experiment 1.
The stock solutions of glucose 6 -phosphate and analogue X 
were made up in 5mM-Tris-base buffer pH 7.5, and the solutions were 
added to diluted suspensions of mouse lymphoma cells entering 
exponential growth phase. Cell suspensions containing glucose 6 - 
phosphate (0.71mM) had no effect on cell proliferation displaying a 
growth curve identical to that of the control suspensions (in 150mM 
saline) (Figure 25). Addition of analogue X (0.95mM) on the other 
hand, appeared to have a cytostatic effect on cell proliferation 
(Figure 25). 20% of cells incubated in the presence of analogue X
were dead as judged by uptake of trypan blue. Centrifugation and 
resuspension in fresh medium demonstrated that even at concentrations 
of analogue X as low as 30yM (by enzymic assay) no cell proliferation 
was observed.
After 150 hr incubation no glucose 6 -phosphate was shown to 
be present (determined enzymically) in cell suspensions initially 
containing glucose 6 -phosphate. In contrast after 150 hr incubation 
0.85mM analogue X was present in cell suspensions initially containing 
0.95mM analogue (representing 11% loss of phosphonate).
Experiment 2 .
After dissolving analogue X in 5inM-Tris-base buffer pH 7.5, 
the pH was read (ph 4.0) and adjusted with Tris-base to pH 7.5. The 
stock solutions were added to diluted suspensions of mouse lymphoma 
cells entering exponential growth phase. Neither glucose 6 -phosphate 
nor analogue X had any effect on cell proliferation with growth curves 
identical to those of control samples (Figure 26).
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Again glucose 6 -phosphate present in the medium had 
decreased, 0.016mM being present after 60 hr (a decrease of 85% from 
its initial concentration of 1.08mM). Control experiments in which 
l.OmM glucose 6 -phosphate was added to medium A  and incubated without 
cells at 37°C showed that the concentration of glucose 6 -phosphate 
dropped to 0.74mM after 45 hr. The greater loss of glucose 6 -phosphate 
in the presence of cells clearly points to a cell-mediated effect 
which could result either from extracellular phosphatase action or 
from transport into the cells. The concentration of analogue X fell 
from 1.02mM to 0.88mM (a fall of 14%) over the 70 hr incubation in 
the presence of mouse lymphoma cells. It is possible that the 14% 
reduction in analogue concentration reflects its transport into 
lymphoma cells but this was not further investigated in view of the 
apparent lack of effect of the analogue on cell growth and the limited 
supplies of sample available.
Addition of glucose 6 -phosphate and its analogue to lymphoma 
cells in late exponential growth gave similar results (Figure 27) 
in which neither compound appeared to affect cell proliferation. 
Incubation again resulted in major loss of glucose 6 -phosphate and 
much less reduction of analogue in the cell medium.
The inhibition of cell growth effected by analogue X in 
experiment 1 clearly resulted from pH changes following addition of 
analogue (in the free acid form) in contrast glucose 6 -phosphate 
was added as the disodium salt to the buffered cell suspension and 
the cytostatic effects of lower pH (4) were subsequently confirmed 
in control experiments. Experiment 1 is included here mainly as a 
cautionary note. The conclusion to be drawn from the exploratory
-165-
in vivo study of analogue X is that although some uptake into cells 
might occur there are no dramatic inhibitory metabolic effects.
The greater loss of glucose 6 -phosphate compared with that of its 
analogue in the extracellular medium could arise from resistance of 
the analogue of phosphatase cleavage or to its reduced transport into 
the cells. Resistance to phosphatase action on the part of analogue X 
is, of course, to be expected, is common to phosphonate analogues of 
this type, and most likely explains the above differences. There is 
some evidence for transport of analogue X into the lymphoma cells 
from these experiments and it may be that use of a suitably-blocked 
non-polar derivative might give rise to significant cytostatic action. 
Overall, however, the initial results were not considered to be 












h o u r  s 80 15 0
F i g u r e  25 E x p e r i m e n t  1. E f f e c t  of g l u c o s e  
6 - p h o s p h a t e  a n d  a n a l o g u e  X on cell p r o l i f e r a t i o n  
of m o u s e  l y m p h o m a  c e l l s  ( L S 1 2 1 0 ) ,  G r o w n  in
m e d i u m  A pl us; 0 . 1 5 M  N a Cl  (a tv) ; 0 , 7 1  m M  g l u c o s e
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F i g u r e  26 E x p e r i m e n t  2. E f f e c t  of g l u c o s e  
6 - p h o s p h a t e  a nd  a n a l o g u e  x on c e l l  p r o l i f e r a t i o n  
of m o u s e  l y m p h o m a  c e l l s  ( L S 1 2 10 ) .  G r o w n  in
M e d i u m  A; 0 . 1 5 m  N aC l  (A--------a); l . O S m M  g l u c o s e
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F i g u r e  27 E x p e r i m e n t  3. E f f e c t  of g l u c o s e  
6 - p h o s p h a t e  a nd  a n a l o g u e  X on ce ll p r o l i f e r a t i o n  
of m o u s e  l y m p h o m a  c e l l s  ( LS 1 2 1 0 ) .  G r o w n  in m e d i u m
A; 0 . 1 5 M  N a C l  (©------ ©) 1.0 m M  g l u c o s e  6 - p h o s p h a t e
(O----- O) ; 1 .0 2  m M  a n a l o g u e  X (□----- □) .
A d d i t i o n  a f t e r  2 0hr e x p o n e n t i a l  g r o w t h .
Preliminary study of the interaction of ]D-glucose
6 -fluorophosphate with glucose 6 -phosphate dehydrogenase
“169 -
INTRODUCTION
Enzymic transferase reactions using a cofactor can be general­
ised in the following form
S + EX ^  SX + F
where S is the substrate and F is the cofactor bearing a group X that 
is to be transferred to the substrate as shown in Figure 28.
Figure 28
L _ l
When the group X is replaced by B, a group that cannot be transferred, 
an inhibitor results. If B has the ability to alkylate some nucleo- 
philic group within the active site (endoalkylation) to form a covalent 




Similar inhibition of the active site can occur if an alky­
lating group (B) is positioned on the substrate, so as not to inter­
fere with substrate binding at the active site, but in a place such 
that it can bridge to some nucleophilic group on the enzyme surface 
outside the active site, (exo-alkylation), then covalent-bond for­




this covalent bond between inhibitor and enzyme has formed, the 
enzyme is blocked from any further reactions with the natural sub­
strate. Thus inactivation tends to be very fast (accelerated- 
neighbouring group reaction) and as only one molecule of the 
irreversible inhibitor is necessary to block one enzyme molecule, 
inhibition constants tend to be very small. The potential of this 
concept as a general method for enzyme study was appreciated by 
Baker (1967) who coined the phrase "active-site-directed irreversible 
enzyme inhibitors." Baker used this concept extensively in investi­
gations designed to produce therapeutically-useful enzyme inactivators.
Thus active-site-directed irreversible inhibitors of enzymes 
are designed to combine two requirements; specific binding at the 
active site and covalent attachment to a group on the enzyme in or 
near the active site.
The fluoro-phosphonate analogue CXXIÏ is an analogue of glucose 
6 -phosphate and, in view of its steric similarities to the latter, 
might be expected to mimic the natural substrate in its interaction 
with an enzyme active site. Furthermore the fluoro-phosphonate moiety 
is a potential acylating agent which is capable of forming a covalent 
linkage with a suitably-placed nucleophilic group on the enzyme. 
Phosphonate CXXII is potentially a more useful metabolic inhibitor 
than the fluoro-phosphate CXXIII which is likely to be much more suscep­
tible to inactivation by phosphatase activity in an in vivo situation. 








was carried out by using the fluoro-phosphate CXXIII in preference to 
phosphonate CXXII in view of the more ready availability of a synthetic 




Glucosamine 6 -phosphate was purcheased from Boehringer Corp 
(London) Ltd, W.5. U.K. Thin layer chromatography was carried out with 
silica gel, particle size 0.05 - 0.2 mM obtained from Merck, Darmstadt 
W. Germany. 2, 3, 4 tribenzyl a D^-gluco fluorophosphoramidate (CXXV ) 
was the generous gift of Dr. C.R. Hall. Reagents used in work described 
earlier in this thesis were obtained from sources previously quoted and 
all other chemicals were purchased from BDH Chemicals, Poole, Dorset,
UK. Thin layer chromatograms were visualised with spray reagent C 
(0.75 gm cysteine di-hydrochloride in 20 ml 50% ethanol, 25 ml 60% con­
centrated H^SO^).
Initial rates of glucose 6 -phosphate dehydrogenase assays were 
followed as described earlier (pagel02). Difference spectra were mea­
sured on a SP 1800 Unicam spectrophotometer.
All concentrations of «  D — glucose 6 -fluorophosphate quoted in 
the text assume 100% conversion of the benzylated derivative (CXXVl) 




The synthesis of ^ - D -gluco 6 -fluorophosphate (CXXIII) was
(initially) carried out by Dr. C.R. Hall, at C.D.E. Porton Down,
31
Wiltshire, UK. The p n.m.r. suggested that the final product 
(CXXIII) had a half-life measured in hours; immediately after iso­
lation of the product it contained a 2 : 1  ratio of expected product 
(CXXIII): cyclised product (CXXIV). After 2 days this ratio had
changed to approximately 1:4 (CXXIII:CXXIV) and after 6 days to 1:25 











As the intermediate, benzyl 2, 3, 4 - tri 0-benzyl a-]D -gluco
6 -fluorophosphoramidate (CXXV) was stable it was convenient to store 
this compound which represents the starting material for the work de­
scribed here. When experiments were ready to be carried out with the 
fluoro-acid (CXXIII) the benzylated fluorophosphoramidate deritative 
(CXXV) was hydrogenolysed and the product, CXXIII, was worked up rap­
idly as possible (excess quantities of palladium catalyst were used in 
the hydrogenalysis in order to minimise the effect of internal cycli­
sation to the cyclic product (CXX ) (scheme 8 ).
Scheme 8
—174 —
(CH^ )2N-P- HO—P—0 —CH
H /H^0_.
L X X V I
HO-P-O-CH
C X X V
Benzyl 2, 3, 4-tri-O-benzyl- a -D-gluco b-fluorophosphate (CXXVI)
A  mixture of the diastereoisomers (at the phosphorus atom) of the 
flurophosphoramidate (CXXV) (39 mg) was dissolved in acetone (10 ml)
and 4 M -  HCl (1 ml) was added dropwise . The solution was allowed
Qjn 4"
to stand at room temperature for 2  hr., poured into excess doubly- 
distilled water and extracted with chloroform. The organic phase was 
dried (MgSO^) and concentrated to give Benzyl 2,3,4-tri-O-benzyl - a  - 
D-gluco 6 -fluorophosphate (CXXVI) (20 mg, yeild 60%). The production 
of CXXVI was monitored by t.l.c (Rf CXXVI, 0.0; CXXV 0.45 (ether ; 
light petroleum, 2:3)). 
a -D-gluco 6 -fluorophosphate (CXXIII)
The benzylated derivative (CXXVI) (20 mg) was immediately dissolved in 
ethanol ( 1 0  ml), hydrogenolysed over 1 0 % palladium on charcoal (0 . 1  g) 
at room temperature and atmospheric pressure, until hydrogen uptake 
ceased (uptake 5.2 ml, theoretical 3.05 ml. 40 mins, figure 28). The 
solution was filtered (over celite), washed with hot ethanol and con­
centrated to 7.3 ml to give a solution of a -D-gluco 6 -fluorophosphate 
CXXIII. There was at this point no trace of startling material CXXVI 
by t.l.c. (Rf CXXVI, 0.3; CXXIII 0.0 (benzenermethanol;acetone, 8:2:2)),
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1. Effect of oc-D-glucose 6 -fluorophosphate (CXXIII) on glucose 
6 -phosphate dehydrogenase at various pH values.
Glucose 6 -phosphate dehydrogenase was diluted to 1 x 10 ^ # 
in 100 mM-Tris-HCl buffer containing 1% bovine serum albumin and ad­
justed to the required pH (7.0, 7.5 or 8.0) with 2 M-NaOH. Each 
enzyme solution was incubated in the presence of 0.28 mM - a-D- 
gluco 6 -fluorophosphate (0.48 mM in the case of pH 7.0)
The activity of the enzyme solutions containing the f luoro-acid 
(CXXIII) was measured with a standard assay containing 0.4 mM - glucose 
6 -phosphate and 0.1 mM-NADP in 100 mM-Tris-HCl, adjusted to the re­
quired pH (7.0, 7.5 or 8.0) with 2 M  NaOH in a 1 cm - pathlength cell 
(total volume 3.005 ml). Activities were assayed at intervals of time 
and compared with that of a control enzyme solution lacking the fluoro- 
acid. Reactions were initiated by the addition of enzyme ( 5 j 4 l ) ,  
(Figure 32 ). At none of the three pH values tested did a-D-glucose 6  —  
fluorophosphate (CXXIII) inhibit the activity of glucose 6 ~phosphate 
dehydrogenase over a period of 24 hours (Figure 29). Even when in 
nearly 5000 fold excess (48 mM / 0.0001 mM, CXXIV / enzyme) over the 
enzyme, ci-^ glucose 6 -fluorophosphate did not detectably inhibit the 
enzyme. These results were repeated in a series of 5 experiments.
2. Difference Spectra
If a-D-glucose 6 -fluorophosphate reacts at the active site of 
the enzyme in a similar manner to that of glucose 6 -phosphate ^ne 
would expect a close similarity in the difference spectra for (I) nat­
ive enzyme versus enzyme plus excess glucose 6 -phosphate and ())
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native enzyme versus enzyme plus excess a-D-glucose fluorophosphate. 
However no meaningful difference spectra were observed in either case 
between the absorbances at 200 and 700 hM ,
3. Substrate Activity of a-D-glucose 6 -fluorophosphate
Within 2hr of hydrogenolysis 0.18mMa-£-glucose 6 -f luorophosphate showed no 
substrate activity towards glucose 6 phosphate dehydrogenase in assays 
run at 3 different pH values (7.0, 7.5 and 8.0). A small endogenous 
rate (0.001 OD/min) was observed in assays containing a-D-glucose 
6 -fluorophosphate prior to addition of enzyme.
4. Competitive inhibition of glucose 6 -phosphate by a-D-glucose 
6 -fluorophosphate on glucose 6 -phosphate dehydrogenase
Reaction mixtures contained varying concentrations of glucose
6 -phosphate (12.5 - 243 yM) and a-D-glucose 6 -fluorophosphate (0, 130 
+ .
or 2 6 0  qiM), NADP concentration was held constant (62 yM) in 100 mM- 
Tris-base buffer adjusted to pH 7.5 with 2 M-HCl in a 5 cm pathlength 
cell (total volume 5.005 ml). Reactions were initiated by the addition 
of enzyme (0.05 h g in 5 y 1 of buffer containing 1% bovine serum 
albumin). A small endogenous rate (0.003 OD/min) was observed in 
assays containing a-]D-glucose 6 -fluorophosphate prior to addition of 
enzyme. 0.13 and 0.26 mM concentrations of aD-glucose 6 -fluorophosphate 
appeared not to competitively inhibit glucose 6 -phosphate dehydrogenase.
5. Competitive inhibition of glucose 6 -phosphate dehydrogenase by 
glucosamine 6 -phosphate.
Reaction conditions were as described in 4 (above), except that
—J.77 —
glucosamine 6 -phosphate replaced a-D^-glucose 6 -fluorophosphate. 
Glucosamine 6 -phosphate was shown to be a competitive inhibitor with 
respect to glucose 6 -phosphate (Figure 33) with a value of 1.48 mM
in general agreement with the findings of Glaser and Brown (1956).
—17 8-
DISCUSSION
a-D-glucose 6 -fluorophosphate was found not to be an active 
site - directed irreversible inhibitor of glucose 6 -phosphate dehydro­
genase. Even when the compound was used in 5000 fold excess of the 
enzyme no inhibition was observed over a 24 hr period. In contrast 
Bromohydroxyacetone phosphate, a potent active side directed irrever­
sible inhibitor, inactivated triose phosphate isomerase from chicken 
muscle in 1.2 fold excess within 5 min and the inactivation reaction 
was too fast for convenient study of the inactivation kinetics. (De La 
Mare et ^  1972) The failure of the analogue to act as an inhibitor
cannot be explained by its internal cyclisation reaction, for even i^ 
\jb cyclised 1000 times faster than the rate observed (by C.R. Hall), in­
hibition of the enzyme should be easily detected.
Furthermore, a-^-glucose 6 -fluorophosphate did not appear to
r
be a substrate for or competitive inhibitor of glucose 6 -phosphate de- 
-4 .
hydrogenase at 10 m concentrations. One possible explanation for 
lack of observed inhibition could be the result of adding a-D- 
glucose 6 -fluorophosphate in a solution of ethanol. However controls 
containing only ethanol were used to counterbalance any effect 
ethanol might have on the assays. To check that the assay system 
worked, glucosamine 6 -phosphate was shown to produce product inhi­
bition of glucose 6 -phosphate dehydrogenase. (Figure 30) The cause
of the endogenous rates observed prior to addition of glucose 6 -
-4
phosphate dehydrogenase in assays containing 1 0  m  quantities of 
a -p^-glucose 6 -phosphate is not known, however it could possibly be 
the result of ethanol mixing with aqueous solution. (Occasionally 
control assays containing ethanol alone displayed similar endogeneous
-179-
rates . )
The work-up of the benzylated fluorophosphoramidate (CXXV) 
was repeated 5 times, on no occasion did the product behave as an ac­
tive site directed irreversible inhibitor of glucose 6 -phosphate 
dehydrogenase.
In favourable cases, where the amino acid composition around 
the active site is known, it may be possible to design the reagent to 
react with a particular postulated catalytic function. In this instance 
such information is not know at the present time and it is possible 
that no suitably-reactive nucleophilic groups are available for 
neighbouring group-type reactions.
A  less likely hypothesis for the lack of observed inhibition 
by a-D-glucose 6 -fluorophosphate stems from the fact this compound 
spontaneously cyclises (indicating the reactivity of the fluorine 
leaving grouping). Thus there is the possibility that a-D-glucose 
6 -fluorophosphate may react indiscriminately with any suitably- 
reactive nucleophilic groups present on the enzyme, which would have 
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G E N E R A L  C O N C L U S I O N S
The phosphonate analogues synthesised and tested in the 
presently-described work have been shown to behave qualitatively 
like their respective natural-occurring phosphates in enzymic 
interactions but less effectively. Similar instances of such 
behaviour have been quoted in the Introduction section to this 
thesis and the most likely explanations in all cases involve 
assumptions of slightly-changed geometry around the CHg-CHg-P 
linkage region compared with that of CHg-O-P, together with possible 
loss of oxygen-enzyme interactions in the phosphonate case.
Such changes might well be expected to lead to decreased affinity 
of the analogue for the enzyme active site. As has been detailed 
in the Introduction section, however, this is not always the case 
and some phosphonate analogues have been shown to behave as 
effectively as the natural-phosphates in their interactions with 
certain enzymes. No consistent pattern has emerged and it seems 
that although decreased interaction with enzymes is the most likely 
result of replacing CH^-O-P of a natural phosphate with CHg-CHg-P 
each system should be individually checked experimentally. The 
most likely potential of phosphonate analogues of naturally-occurring 
phosphates probably lies in their use in clear-cut situations such as 
their application as probes,to decide whether a biochemical effect 
observed using a natural phosphate results from phosphate-cleavage 
or simply from its binding to a suitable receptor site. The 
stability of the C-P bond in biochemical systems certainly allows 
the possibility of prolonging the in vivo life of any phosphonate 
metabolic inhibitor and despite the negative results obtained
“ 184-
using the glucose 6 -phosphate dehydrogenase system described 
here the potential of phosphonates as the basis of active-site 
directed irreversible inhibitors remains real at the 
present time.
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